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Abstract 
Colorectal cancer (CRC) is the second-highest cause of cancer deaths in the 
United States. A comprehensive understanding of disease development and progression is 
critical for the advancement of effective diagnostic and treatment methods for CRC 
patients. Forward genetic screens have identified numerous candidate genes that may be 
driving tumor development and progression (Starr et al. 2009). Two identified candidate 
genes are potassium voltage-gated channel subfamily Q member 1 (KCNQ1) and cystic 
fibrosis transmembrane conductance regulator (CFTR). Previous studies show knockout 
of Kcnq1 or Cftr alone causes increased intestinal tumorigenesis in the ApcMin mouse 
model, and low expression of KCNQ1 or CFTR in CRC tumors is associated with poor 
outcomes in human CRC (Than, et al. 2014, 2016). To further investigate the role of 
these genes as CRC tumor suppressors, we harvested intestinal organoids from Kcnq1 
and Cftr knockout (KO) and wild-type (WT) mice and isolated RNA from these 
organoids. Illumina Next-Generation RNA Sequencing and quantitative reverse-
transcriptase PCR was performed using organoid RNA to evaluate and compare gene 
expression. In addition, preliminary phenotypic characterization of organoids derived 
from Kcnq1 and Cftr WT and KO mice was performed. Bioinformatic analysis by Gene 
Set Enrichment Analysis (GSEA) using human cancer datasets further characterized gene 
expression changes in KCNQ1 and CFTR low-expression phenotypes. Our data show 
Kcnq1 is localized to the stem cell compartment of the small intestine, and loss of Kcnq1 
and Cftr effect gene expression in isolated organoids as well as primary tissue. Loss of 
these tumor suppressive genes alter specific biological pathways, including cholesterol 
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biosynthesis and the unfolded protein response, that may lead to cancer development and 
progression. 
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Introduction 
Colorectal cancer 
Colorectal cancer (CRC) is the second-highest cause of cancer deaths in the 
United States, resulting in approximately 136,830 new cases nationwide each year and 
50,310 deaths per year due to CRC in 2014 (Kasper et al. 2012). A comprehensive 
understanding of disease development and progression is critical for the development of 
effective diagnostic and treatment methods for CRC patients, which currently are lacking 
in efficacy. Many benign polyps, adenomas, are detected during routine colonoscopies 
and such polyps can be surgically removed. Individuals diagnosed with early stage CRC 
(Stages I and II) are often considered cured by surgery alone and do not receive adjuvant 
chemotherapy. Stage I cancers consist of superficial epithelial lesions that have not 
invaded nearby lymph nodes and have begun to penetrate the underlying submucosa 
(Kasper et al. 2012). Colorectal cancer is diagnosed as Stage II if there are tumors present 
that penetrate through the muscularis of the tissue, but have not yet completely invaded 
the muscularis and have not spread to regional lymph nodes (Harrison’s). However, 25% 
of Stage II patients experience disease relapse and die within 5 years. There is currently 
no method of identifying these and other at-risk individuals. Later stages of CRC become 
more difficult to treat, as they are defined as cancers that have spread to the regional 
lymph nodes (Stage III) or as cancers that have metastasized to distant sites such as the 
liver or lung (Stage IV). Surgical resection of affected organs is a possible treatment for 
Stage IV patients, but 5-year survival is below 30%. Due to the unacceptable survival 
rates of Stage IV patients, there is an urgent need for new therapies. Currently, gaps in 
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our knowledge prevent us from developing more efficient diagnosis and treatment 
measures, both to identify patients at higher risk for relapse and thus in need of increased 
disease surveillance and more aggressive treatment, and for patients suffering from the 
later stages of cancer (III and IV). Research to determine the functional mechanisms 
underlying CRC development as well as identifying potential prognostic and diagnostic 
biomarkers will greatly contribute to the effort to establish more effective diagnosis and 
treatment. 
The Intestinal Stem Cell Compartment 
Colorectal cancer arises from the intestinal epithelium. Small intestinal tissue is 
composed of crypts and villi (Figure 1), while the large intestinal tissue lacks the 
absorptive villi. At the base of the crypt compartment reside five to six self-renewing 
stem cells (Sato et al., 2009).  These cells produce transit amplifying progenitor cells, 
which proliferate but may only divide several times before differentiating (Sato et al., 
2009). Differentiated cells that result from progenitor cells include enterocytes, goblet 
cells, Paneth cells (not present in the colon), and enteroendocrine cells (Sato et al., 2009).  
In the small intestine, epithelial cells form villi, with rapidly dividing cells from 
the crypt bottom pushing and shedding older, apoptotic cells near the tip of the villi. 
Apoptosis occurs approximately three days after epithelial cells differentiate and migrate 
upwards (Sato et al., 2009). Paneth cells do not migrate upwards, but remain in contact 
with stem cells near the base of the crypt and are responsible for maintaining the 
microenvironment of stem cells (Sato et al., 2009).  
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On average, an individual epithelial cell’s life cycle is less than a week long, and 
in the mouse, approximately 200 new cells are generated per crypt each day (Reya and 
Clevers, 2005). In the adult intestinal tissue, progenitor proliferation, cell differentiation, 
and apoptosis are regulated by stem cells in the crypt compartment (van der Flier and 
Clevers, 2009). These stem cells reside in a tightly regulated microenvironment. The 
stem cell niche is formed by the subepithelial myofibroblasts, which secrete various 
growth factors and cytokines to promote proliferation of the epithelium (van der Flier and 
Clevers, 2009). The tight regulation and cross-talk between stem cells, Paneth cells in the 
small intestine and Paneth-like cells in the large intestine, and the underlying 
mesenchyme maintains the delicate homeostasis of the tissue in regards to proliferation, 
differentiation, and apoptosis. Dysregulation of these cellular signals leads to abnormal 
growth, and in some cases, colon cancer.  
 
Figure 1 Intestinal stem cells directing proliferation of progenitor cells and the formation 
of the villi, in normal versus adenoma tissue (Clevers, 2006).  
 
Molecular Regulation of the Intestinal Tissue 
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Homeostasis of intestinal tissue is tightly controlled by multiple signaling 
pathways (Sato and Clevers, 2013). Signaling pathways create a feedback that maintains 
the balance between cell proliferation, and apoptosis in a tissue that experiences complete 
turnover very rapidly. In addition, these signaling pathways direct progenitor cells to cell 
lineage specification, resulting in the differentiation of cells to the secretory lineage 
(Paneth cells, goblet cells, and enteroendocrine cells) or the absorptive lineage 
(enterocytes) (van der Flier and Clevers, 2009).  
The Wnt/β-Catenin canonical signaling pathway is highly conserved and is crucial 
for growth and patterning during development (Farin et al., 2016). Although the 
mechanism of Wnt protein secretion and signaling is well-developed in Drosophila, 
limited information exists on endogenous Wnt protein distribution in vertebrates (Farin et 
al., 2016). Wnt is structurally unique due to its insolubility, high number of cysteine 
residues, and covalently attached N-terminal fatty acid chain, which increases its binding 
to cellular surfaces (Clevers, 2006). In the intestinal crypt, stem cell self-renewal, 
proliferation, and differentiation are coordinated along a Wnt gradient (Farin et al., 
2016). Wnt is secreted by Paneth cells and travels away from its source in a cell-bound 
manner via cell diffusion, leading to the establishment of the Wnt gradient along the 
crypt (Farin et al. 2016). Wnt binds to its cognate Frizzled receptors on neighboring stem 
cells, where its signaling cascade leads to activation of Wnt target genes.  
Wnt is the primary driving force behind proliferation of epithelial cells in the 
intestine. The canonical Wnt/β-Catenin pathway is activated upon Wnt binding to 
Frizzled transmembrane receptor proteins. This binding interaction recruits additional 
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transmembrane molecules LRP5 and -6 and Mesd to Frizzled, which further activates the 
signaling cascade (Clevers, 2006). Once Frizzled-LRP is bound by its ligands, Frizzled 
interacts with the cytoplasmic protein Dishevelled. Wnt binding to Frizzled/LRP also 
induces the phosphorylation of the cytoplasmic tail of LRP, which allows for the docking 
of the cytoplasmic Axin protein. Phosphorylation of Axin by CK1 family kinases 
promotes the Dishevelled and Axin heterodimer to cooperatively mediate downstream 
signaling activation events. β-Catenin is the key effector of the canonical Wnt pathway 
signaling cascade. In the presence of Wnt, the tumor suppressor protein Axin is 
phosphorylated and bound in its heterodimeric state at the membrane, preventing its 
interaction with β-Catenin and the Adenomatous Polyposis Coli (APC) protein. The 
recruitment of Axin away from the APC destruction complex prevents the degradation of 
β-Catenin by the destruction complex, thus allowing β-Catenin to translocate to the 
nucleus, where it dislocates the transcriptional repressor Groucho from TCF to promote 
the transcription of Wnt target genes. In the absence of Wnt, Axin binds to the APC and 
β-Catenin complex, initiating the phosphorylation of β-Catenin by CK1 kinases, which 
consequently target β-Catenin for ubiquination and degradation by the proteasome. This 
prevents the translocation of β-Catenin to the nucleus and the subsequent transcription of 
Wnt target genes. (Clevers, 2006 and Clevers, 2005, and Clevers, 2012) (Figure 2).   
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Figure 2. Wnt signaling stimulates transcription of target genes by β-Catenin activation, 
while the absence of Wnt signaling inhibits transcription of these genes. Abbreviations in 
the figure: β-Cat- β-Catenin, APC- Adenomatous Polyposis Coli, Fz- Frizzled.  
 
The transcriptional programs activated by Wnt signaling have been described as 
necessary for the maintenance and activation of stem cells in the intestinal epithelium 
(Reya and Clevers, 2005). Wnt target genes promote cell proliferation and tissue 
expansion as well as cell fate determination (Reya and Clevers, 2005). A study of 
neonatal transgenic Tcf4-/- mice showed that the absence of this transcriptional activator 
that is regulated by Wnt signaling did not affect the villus of the epithelial compartment, 
but obliterated the crypt progenitor compartment (Reya and Clevers, 2005). These results 
suggest Wnt signaling is required for maintenance of the crypt progenitor phenotype, and 
is a positive feedback on epithelial stemness.  
The Wnt pathway is of interest in colorectal cancer because mutation of the APC 
gene is found in 90% of sporadic colorectal carcinomas (Kinzler and Vogelstein, 1996). 
The APC protein constrains Wnt/β-catenin signaling by mediating the degradation of β-
catenin by the proteasome in the cytoplasm (Clevers, 2006). Loss of this degradation 
function results in an excess of β-catenin and increased transcription of genes controlling 
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epithelial stemness. This causes uncontrolled expansion of the stem cell population and 
results in a drastic increase in the number and size of intestinal crypts (Reya and Clevers, 
2005). Heterozygosity of APC in mice and humans, when coupled with an additional 
somatic mutation of APC, causes an expansion of progenitor cells in the crypt, resulting 
in adenomatous tissue development in the intestine (Sansom et al., 2004). The ApcMin 
mouse carries one inherited germline defective allele of Apc and is a common 
experimental model for colorectal cancer, as it provides a genetic background that 
provides an activating mutation of the Wnt cascade, which current evidence suggests is 
an initiating event in CRC development (Reya and Clevers, 2006).  
 Notch signaling is also involved in the feedback that maintains homeostasis of 
intestinal tissue. The Notch pathway is important for intestinal cell fate decisions, as it 
directs the differentiation of secretory cell lineages. Like Wnt signaling, the Notch 
pathway is essential for the maintenance of the undifferentiated and proliferative state of 
the crypt compartment (van der Fliers and Clevers, 2009). It is known that Notch 
regulates cell differentiation and plays a role in tumorigenesis, but our understanding of 
the mechanism is poor. In colorectal cancer, altered feedback from Notch prevents cells 
from progressing to their differentiated state (van der Flier and Clevers, 2009). 
Undifferentiated cells can form tumors, eventually resulting in cancerous growth (van der 
Flier and Clevers, 2009). Upon activation, Notch undergoes a proteolytic cleavage and 
translocates to the nucleus of the cell where it acts as a transcription factor to turn on 
expression of target genes (Sikandar et al., 2010). Inhibition of this signaling in mice 
results in a negative feedback of maintenance of epithelial stemness, and an increase in 
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the goblet cell population (Sikandar et al., 2010). Notch signaling plays an important role 
in the initiation of tumors, as it is a positive feedback on stemness (lack of differentiation 
and proliferation) (Sikandar et al., 2010).  
Bone morphogenic protein (BMP) provides negative feedback on intestinal stem 
cell self-renewal (He et al., 2004). Although the exact mechanism is not fully understood, 
inactivation of BMP in mice alters intestinal tissue homeostasis and increases stem cell 
and progenitor cell populations, eventually leading to polyposis (He et al., 2004), 
supporting BMP’s function as a stem cell inactivator. BMP normally functions by 
suppression of Wnt signaling, thus and creating a negative feedback on stem cell self-
renewal (He et al., 2004). Noggin is a secondary signaling molecule which inhibits the 
action of BMP, preventing the inhibition of Wnt. BMP is secreted by neighboring Paneth 
cells in response to increased stem cell proliferation; its signal then inhibits Wnt, creating 
a negative feedback loop on epithelial stemness. 
Wnt, Notch, and BMP constitute a feedback system that is necessary for 
maintenance of homeostasis between cell proliferation, differentiation, and cell death. 
Cancer is the result of disruption of this homeostasis, via alteration of the many signaling 
pathways that set up this feedback. How one signaling pathway affects another is not 
fully understood, although relationships have been implied (Sikandar et al., 2010).  
Genetic factors contributing to colorectal cancer development 
Colorectal cancer is a disease of genetic alterations that often develops over 
decades and requires several genetic changes to be considered malignant, which is 
characterized by uncontrolled growth (Kinzler and Vogelstein, 1996). Colorectal cancers 
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can be classified as inherited and sporadic. Inherited dominant predisposition syndromes 
are estimated to account for approximately 5% of CRC, and Familial Adenomatous 
Polyposis accounts for 0.5-1% of total cases (Kinzler and Vogelstein, 1996). Familial 
Adenomatous Polyposis (FAP) is a highly penetrant, autosomal dominant syndrome that 
results from the germline mutation of the Adenomatous Polyposis Coli (APC) gene and 
affects 1 in 7,000 individuals (Kinzler and Vogelstein, 1996). FAP patients develop 
hundreds to thousands of benign colorectal polyps that often develop into cancerous 
lesions (Kinzler and Vogelstein, 1996). FAP is important to our overall understanding of 
CRC because the causal genetic defect affects the rate of tumor formation by altering a 
key gatekeeper gene, APC (Kinzler and Vogelstein, 1996). APC is also mutated in ~80% 
of sporadic cases of CRC; thus, better understanding its role in FAP will lend to an 
understanding of colon cancer tumorigenesis overall. 
CRCs are further classified by their genetic instability as either microsatellite 
instable or chromosomal instable. Microsatellite instability is caused by defects in the 
cellular mismatch repair machinery and has been widely studied in many tumor types 
(Fodde et al., 2001). Chromosomal instability is characterized as tumors that exhibit 
defective chromosomal segregation during cell division, which leads to variation in 
chromosome numbers (aneuploidy) among cells from individual clones (Fodde et al., 
2001). The seminal work investigating the genetic alterations of colon cancers found that 
somatic mutations of KRAS, APC, and P53 were present in most colon cancers, both 
familial and sporadic (Bos et al., 1987; Baker et al., 1990; Cho and Vogelstein, 1992). 
Despite these common limiting genetic mutations or epigenetic alterations, every 
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individual CRC case exhibits as many as a hundred or more mutations, while only a few 
(an estimated 10-20) are causally involved in cancer development. These mutations cause 
CRC by dysregulating important biological processes and many key cellular signaling 
pathways (Saif and Chu, 2010). 
Sleeping Beauty Transposon Mutagenesis Identified Colorectal Cancer Candidate Genes 
 A common and powerful tool for cancer gene identification is forward genetic 
screens in mice utilizing transposons, which are DNA elements that translocate randomly 
throughout the host genome. Mutagenesis by transposon insertion allows for the unbiased 
discovery of novel candidate cancer genes. The genetic changes of human colorectal 
cancers are varied, with respect to both genetic and epigenetic alterations. Starr et al. 
utilized a Sleeping Beauty (SB) system to identify which genetic alterations are causally 
involved in intestinal tumorigenesis (drivers) and which have little functional impact in 
cancer development (passengers) (Starr et al., 2009). To identify these driver genes, Starr 
et al. inserted mutagenic SB11 transposase cDNA preceded by a LoxP-flanked stop 
cassette into the Rosa26 locus, then crossed these transgenic mice to Villin-Cre 
transgenic mice to restrict transposase activation to the gastrointestinal tract epithelium 
(Starr et al., 2009). When expressed, the SB transposase activated the transposition of the 
mutagenic transposon T2/Onc, which contains a murine stem cell virus long terminal 
repeat and splice donor site (Starr et al., 2009). This characteristic of T2/Onc can 
deregulate the expression of a proto-oncogene. On the other hand, T2/Onc also has splice 
acceptor sites and a bidirectional poly(A) signal which can inactivate the expression of a 
tumor suppressor gene (Starr et al., 2009). Mice that developed tumors were sacrificed, 
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and DNA was isolated and sequenced from those tumors to identify common insertion 
sites of the transposon, which are defined as insertion sites which occurred at a higher 
rate than that which is expected due to random chance (Starr et al., 2009). These 
candidate driver genes were suspected to be involved in colorectal cancer, and thus it is 
crucial to first determine whether these genes are causally involved in cancer 
development, and whether this involvement is tumor suppressive or oncogenic. 
Furthermore, two of these candidate genes, KCNQ1 and CFTR, were used to inform the 
specific gene targets of this thesis. 
KCNQ1 
KCNQ1 Physiological Function 
The KCNQ1 gene encodes a voltage-gated potassium channel widely expressed 
throughout the body, including the myocardium, inner ear, stomach, pancreas, and 
intestine (Than et al., 2013). The KCNQ1 channel protein is composed of six 
transmembrane-spanning α-helices and a pore loop, with typical potassium channel pore 
signature sequence structure. KCNQ1 is a voltage-gated channel opened by increasing 
membrane depolarizations. Once opened, the channel creates slowly activating and 
deactivating potassium currents (Jespersen et al., 2005). 
KCNQ1 is a key regulator of ion homeostasis and modulates water and salt 
transport in epithelial tissues. The epithelium serves as a functional barrier between the 
external and internal environment, and transport of substances through this barrier is 
dependent on the activity of channels. Potassium channels, such as KCNQ1, maintain a 
membrane potential necessary for transepithelial transport. KCNQ1 is expressed in many 
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epithelial tissues and has been demonstrated to modulate transepithelial transport as well 
as the secretion of potassium (Diener et al., 1996).  
KCNQ1 channels secrete potassium across the basolateral membrane in the 
intestinal epithelium. Continuous transepithelial transport is dependent on basolateral 
potassium conductance modulated by KCNQ1. Chloride enters the basolateral membrane 
by cotransport with potassium and sodium, and is subsequently secreted through CFTR 
chloride channels located on the apical membrane. This secretion is dependent on 
basolateral potassium conductance, which is modulated in part by KCNQ1. 
In the mouse small intestine expression of Kcnq1 occurs in a gradient, with the 
highest expression in the duodenum and proximal jejunum and the lowest expression in 
the ileum (Demolombe et al., 2001; Dedek and Waldegger, 2001). In the mouse large 
intestine, Kcnq1 expression is highest in the distal colon (Vallon et al., 2005; Warth et 
al., 2002). On the cellular level, Kcnq1 is expressed in the base of the intestinal crypt 
(Fig. 1, Alwan, unpublished data). The localization and expression of KCNQ1 in the 
intestinal epithelium suggests a role for the regulation of intestinal stem cells, which are 
also located at the base of the crypt.  
KCNQ1, Ion Channels, and Cancer 
Ion transporters and the voltage gradients they create are involved in development 
and proliferation (Morokuma et al., 2008). Ion channels regulate the microenvironment 
of stem and tumor cells, thus regulating their behavior (Morokuma et al., 2008). Stem 
cells of the intestinal crypt receive signals from their environment. These signals include 
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not only ligands (such as Wnt, Notch, and BMP), but also those of electrical nature, such 
as ion currents and voltage gradients (Morokuma et al., 2008).  
Voltage-gated potassium channels functionally regulate progression through the 
cell cycle (Blackiston et al., 2009).  Molecular physiology studies show other voltage-
gated K+ channels are inhibited upon cell maturation (Kunzelmann, 2005). But, 
cancerous cells maintain the activity of these ion channels and highly express them past 
cell maturation, which increases proliferation (Kunzelmann, 2005). Mutation of KCNQ1 
disrupts ion homeostasis and may alter the complex signaling required for normal cell 
proliferation. Identifying if and how this change in ion conductance causes oncogenic 
phenotypes in intestinal epithelium is key to a comprehensive understanding of CRC. 
Evidence Supporting KCNQ1 as a Tumor Suppressor in Colorectal Cancer 
 KCNQ1 is a colorectal cancer tumor suppressor gene. A Sleeping Beauty DNA 
transposon mutagenesis screen of intestinal epithelial cells in wildtype mice revealed 
KCNQ1 as a candidate driver gene for intestinal tumorigenesis, as the gene was identified 
as a high frequency common insertion site locus (Starr et al., 2009). In addition, another 
genetic screen in ApcMin  mice by Starr et al. (2011) found Kcnq1 mutations in 13% of 
intestinal tumors analyzed, ranking it as one of the top ten common insertion site genes of 
these genetic screens (Starr et al., 2011). Loss of Kcnq1 promoted tumor progression and 
enhanced tumor multiplicity in ApcMin mice by approximately two-fold in the proximal 
small intestine and colon. cDNA microarray expression studies of distal colon and small 
intestine tissue derived from Kcnq1 knockout mice showed loss of Kcnq1 had a strong 
effect on gene expression. Pathways affected by loss of Kcnq1 included intestinal stem 
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cell-related genes, suggesting further that Kcnq1 is a tumor suppressor by having a role in 
the intestinal stem cell compartment (Than et al., 2013). 
Additionally, clinical data suggests KCNQ1 is a tumor suppressor in colon cancer. 
Microarray gene expression data used to analyze KCNQ1 mRNA expression in 90 stage 
II colon cancer patients found that low expression of KCNQ1 was associated with poor 
disease-free survival (den Uil et al., 2016). In the same study, KCNQ1 protein expression 
was analyzed in a cohort of 386 stage II and stage III colon cancer patients by 
immunohistochemistry of tissue microarrays. These studies found that KCNQ1 may be a 
viable biomarker for prediction of disease recurrence (Starr et al., 2009). A Kaplan-Meier 
plot comparing high KCNQ1 expression and low KCNQ1 expression in colon cancer 
patients against overall survival after hemihepatectomy correlated expression of KCNQI 
and survival time of late-stage CRC, with a substantial survival difference of 23 months 
longer in KCNQ1 high expressing CRC patients (Than et al., 2013).    
CFTR 
Another gene identified as a candidate driver gene of colorectal cancer in a 
Sleeping Beauty Transposon Mutagenesis screen is the cystic fibrosis transmembrane 
conductance regulator (CFTR) (Starr et al., 2009). CFTR encodes an epithelial anion 
channel and mutations of this gene cause cystic fibrosis (CF), a disease which affects 
about 85,000 people worldwide (Bell et al., 2015). CF patients have altered 
gastrointestinal physiology due to deficient anion and fluid transport, including altered 
cellular pH, impaired release and elimination of mucus, abnormal microbiota 
colonization, and dysregulated innate immune responses that lead to inflammation (De 
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Lisle and Borowitz, 2013). Considering these alterations in gastrointestinal physiology, it 
is not surprising that a 20-year cohort study of CF patients in the United States found 
these patients have an increased risk of developing gastrointestinal cancers (Maisonneuve 
et al., 2013).  
CFTR is a cyclic AMP-dependent transporter of Cl- and HCO3
 - in the crypt 
epithelium, where it is most highly expressed in the base of the crypt and is present at 
reduced levels in the villous epithelium (Liu et al., 2012). CFTR was of interest to our lab 
as a candidate gene because the protein’s function is dependent on the function of 
KCNQ1 as KCNQ1 creates a potassium current that enables the dependent Cl- section by 
CFTR. Together, these ion channels play multifunctional roles in processes of ion and 
acid-base transport that are essential to normal crypt physiology (Liu et al., 2012).  
Published data by our lab as well as other researchers suggest a role for CFTR as 
a tumor suppressor gene in colorectal cancer. Than et al. examined CFTR deficiency in 
mouse models and human CRC patients to confirm its role in CRC development implied 
by previous Sleeping Beauty screens. Their data show that loss of Cftr significantly 
enhances tumor multiplicity in both the small intestine and colon in the ApcMin mouse 
model (in both heterozygous and homozygous mutants). Loss of Cftr alone also induced 
tumor formation in both the colon and small intestine of mice, with a >60% penetrance. 
Loss of CFTR expression in stage II CRC human patients showed similar effects, as 3-
year relapse-free survival was 85% in the CFTR high-expressing group, compared to 
56% in the CFTR low-expressing group (Than et al., 2016). Considered together, these 
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results confirm the role of CFTR as a CRC tumor suppressor gene, although the data does 
not inform on the functional mechanism of tumor suppression.  
Biological Pathways of Interest 
 Many biological pathways may influence or play a role in the development of 
colorectal cancer. Specifically, dysregulation in the form of activation or repression of 
normal cellular responses contributes to the development and progression of CRC. The 
identification of these altered pathways as well as the characterization of their oncogenic 
or tumor suppressive effects helps establish a model of CRC carcinogenesis, and can lead 
to the development of more effective treatment and diagnostic measures. Analysis of 
CFTR normal and deficient tissue by Ingenuity Pathway Analysis (IPA) revealed the 
LXR/RXR pathway as an altered pathway due to loss of CFTR expression. Similarly, 
analysis of Kcnq1-deficient organoids by Gene Set Enrichment Analysis (GSEA) 
revealed the unfolded protein response (UPR) was altered due to loss of Kcnq1 
expression. These two pathways were explored further in this thesis. 
The Unfolded Protein Response 
 A known pathway altered in multiple cancers is the unfolded protein response, a 
highly conserved process among taxa initiated in response to endoplasmic reticulum (ER) 
stress due to the accumulation of misfolded proteins. Misfolded proteins in the ER lumen 
are detected by glucose regulated protein 78 (grp78), a chaperone and negative regulator 
of PERK, IRE1, and ATF6 (Kaser et al., 2010). Grp78 binds misfolded proteins in the 
lumen of the ER as well as PERK, IRE1, and ATF6, until the chaperoning capacity of the 
protein is exceeded, in which case the unfolded protein response is activated by Grp78 
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releasing its binding to PERK, IRE1, and ATF6 to instead bind misfolded proteins, 
releasing the inhibition of the three arms of the effector pathway (Kaser et al., 2011). The 
unfolded protein response is initiated by three main signaling pathways; pancreatic ER 
kinase (PERK), activation transcription factor 6 (ATF6), and inositol requiring enzyme 1 
(IRE1) (Kaser et al., 2010). Upon initiation of these signaling pathways, respective 
transcription factors are activated and translocate to the nucleus, where they direct a 
transcriptional program to direct the cellular response to the accumulation of misfolded 
proteins and its consequences (Kaser et al., 2010).  
 The three effector arms, PERK, IRE1, and ATF6, lead to defined transcriptional 
changes that ultimately comprise the unfolded protein response. Upon activation by 
sensing the presence of unfolded proteins, the kinase function of PERK is activated and 
elongation initiation factor 2α (elF2α) is phosphorylated (Harding et al., 2000). elF2α is a 
translation initiation factor that is unable to bind in its phosphorylated state, resulting in a 
halt in protein synthesis (Harding et al., 2000). However, activation factor 4 (ATF4) is 
not inhibited by elF2α and directs the transcription of the CCAAT/enhancer binding 
homologous protein (CHOP), which promotes cell death (Vattem et al., 2004). ATF6 is 
activated by the detection of misfolded proteins in the ER lumen and subsequently 
translocates to the Golgi apparatus, where its transcriptionally active cytoplasmic tail is 
cleaved and directs a transcriptional response to ER stress (Todd et al., 2008 and Haze et 
al., 1999). The final arm of the unfolded protein response, IRE1, dimerizes and 
autophosphorylates upon activation. Two main forms of IRE1 are expressed in mammals: 
IRE1α is ubiquitously expressed, while IRE1β expression is restricted to the intestinal 
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epithelium (Cao and Kaufman, 2012). In its activated form IRE1 cleaves the transcription 
factor XPB1 which causes the transcription factor to be spliced and activated. IRE1 
functions as an endoribonuclease and kinase (Cao and Kaufman, 2012). These pathways 
are illustrated below in Figure 3.  
 
 
Figure 3. The three arms of the unfolded protein response- PERK, ATF6, and IRE1. 
(Kaser et al., 2011, Exp. Cell Research.) 
 
The Unfolded Protein Response and Disease 
 Endoplasmic reticulum stress can be caused by a variety of factors, both intrinsic 
and extrinsic. The most common physiological factor that leads to ER stress is simply an 
increase in protein synthesis, which could be due to cell stimulation by growth factors, 
cell proliferation, differentiation, or senescence (Wang and Kaufman, 2016). In addition 
to these normal cellular stressors, mutations in protein folding genes or defects in UPR 
signaling can induce ER stress (Wang and Kaufman, 2016). The ability of a cell to 
manage ER stress via the UPR is crucial for the maintenance of homeostasis, and thus 
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disruption of these processes can lead to various disease states. Pathologic conditions 
cause changes in the microenvironment that may induce ER stress independently or in 
addition to normal biological stressors, such as inflammation, hypoxia, or nutrient 
deprivation (Wang and Kaufman, 2016). Considering these factors, it is unsurprising that 
ER stress has been found to contribute to the initiation and progression of numerous 
diseases in humans, including neurodegenerative disease, metabolic disease, 
inflammation, and cancer (Wang and Kaufman, 2016).  
 Previous studies have shown ER stress-related genes and proteins display altered 
expression in cancers (Moenner et al., 2007). For example, the expression of ER 
chaperone glucose-regulated protein (GRP) 78/BiP and GRP 94 have been found to be 
altered in at least ten different cancers, including colorectal cancer (Moenner et al., 
2007). Grp78 directly plays a role in the ability of cells to resist proapoptotic challenges, 
implying its influence in cancer development and progression (Moenner et al., 2007). 
The UPR is of interest in cancers that involve secretory cells, such as colorectal cancer, 
which originates from the highly secretory columnar epithelium that lines all mucosal 
surfaces (Kaser et al., 2011). Highly secretory cells (such as Goblet and Paneth cells in 
the intestinal epithelium) are especially vulnerable to ER stress and as such are dependent 
on a functional UPR for homeostasis (Kaser et al., 2011).  
 In addition to the defined UPR role in homeostasis, recent studies have shown 
UPR activity is involved in cell fate decisions (van Lidth de Jeude et al., 2016). 
Colorectal cancer develops from oncogenic mutations that occur in intestinal stem cells, 
which direct and regulate cell proliferation, apoptosis, and differentiation in the tissue. 
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Because cancer develops from dysregulation of intestinal stem cells, studies have aimed 
to directly evaluate the effect of ER stress on stem cells and cell differentiation in the 
intestinal epithelium. During normal cell differentiation, a multitude of transmembrane 
and secreted proteins are produced in the ER, which attracts chaperones such as Grp78 
and shifts them away from their bound position on the three transmembrane UPR 
receptors IRE1α, ATF6, and PERK (Ni and Lee, 2007). These receptors then activate the 
UPR by their respective signaling pathways. A study of the intestinal epithelium by 
Heijmans et al. using genetic and cellular techniques revealed that levels of ER stress and 
UPR activation are low in intestinal stem cells compared to differentiated transit 
amplifying cells (2013). This study also demonstrated that activation of Perk-elF2α 
signaling alone induces intestinal epithelial stem cell differentiation. The data from 
Heijmans et al. show differential activity of ER stress between stem cells and transit-
amplifying cells in the intestinal epithelium, which suggests the ER may regulate 
intestinal epithelial stem cell differentiation.  
 To investigate the function of ER stress and UPR induction in intestinal 
epithelium that has already acquired oncogenic mutations, van Lidth de Jeude et al. 
(2016) generated transgenic mice in which Apc and Grp78 could be conditionally 
knocked-out and harvested intestinal organoids from these mice. As previously described, 
Apc is an important tumor suppressor gene for colorectal cancer and is a negative 
regulator of the Wnt/β-catenin pathway. van Lidth de Jeude et al. found that loss of Apc 
alone resulted in crypt elongation, activation of the Wnt signature, and accumulation of 
intestinal stem cells (2016). This phenotype was completely rescued upon activation of 
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ER stress by additional deletion of Grp78. In Grp78 Apc double knockout mice, stem 
cells were lost and repopulation occurred by non-mutant cells only, which implies these 
double-knockout mice had lost the capacity to self-regenerate (2016). These results, 
along with others, suggest an important role for ER stress and the UPR in regulating 
intestinal stem cell differentiation. Understanding how these biological processes are 
involved in inducing differentiation could lead to functional information about the 
mechanisms of CRC development and progression, and may also be a promising 
therapeutic target. 
Cholesterol Biosynthesis and Homeostasis 
 Cholesterol biosynthesis and homeostasis are crucial for normal cell functioning 
as cholesterol is an important component of cell membranes and is involved in many 
other biological processes. The association between cholesterol metabolism and cancer 
has been thoroughly investigated and it has been shown that proliferating cells increase 
cholesterol uptake. Hyper-proliferative cancer cells maintain high intracellular 
cholesterol through various mechanisms including accelerated endogenous production of 
cholesterol and fatty acids and reduction of cholesterol efflux via membrane transporters. 
The dependency of rapidly proliferating cells on cholesterol biosynthesis and homeostasis 
mechanisms has made this a promising and interesting target for cancer research 
(Gabitova et al., 2014).  
 Cholesterol metabolites interact with several nuclear receptors, which when 
bound by their small lipophilic cognate ligands modulate transcriptional activities. 
Receptors classified in the nuclear receptor superfamily share similar structural 
  22 
organization and contain an N-terminal activating domain, a DNA-binding domain, a 
ligand-binding domain, and a C-terminal activating domain (Moschetta, 2015). The liver 
X receptor (LXR) is a member of the nuclear receptor family and is an established 
ligand-activated transcription factor. LXRs exist as two isoforms, LXRα, encoded by the 
gene NR1H3, and LXRβ, encoded by the gene NR1H2 (Vedin et al., 2013). LXRβ is 
ubiquitously expressed, while LXRα is selectively expressed in metabolically active 
tissues (Bovenga et al., 2015). In the small intestine and colon both LXR isoforms are 
highly expressed (Vedin et al., 2013).  
 LXRs are activated by a metabolite of cholesterol, oxysterol, and regulate the 
expression of genes involved in lipid, cholesterol, and carbohydrate metabolism (Vedin et 
al., 2013). When bound to its cognate ligand, LXR binds to LXR response elements and 
forms a heterodimer with retinoid X receptors (RXRs), which causes a conformational 
change that recruits additional co-activators to displace co-repressors. This opens the 
chromatin structure and allows for assembly of the transcriptional machinery, and thus 
activates transcription of target genes. In the absence of the oxysterol ligand, the 
heterodimer recruits co-repressor complexes, and transcription of LXR target genes is 
inactivated (Moschetta, 2015). LXRs act as global cholesterol sensors, and their 
activation leads to a net reduction of cholesterol by promoting its efflux, limiting its 
absorption, reducing its cellular uptake, and enhancing its conversion to bile acids in 
mice (Bovenga et al., 2015). These LXR-mediated responses play an important role in 
regulating cholesterol metabolism and homeostasis and are thus interesting targets for 
further investigation of how cholesterol is involved in disease states, particularly cancer.  
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LXR Activation and Cholesterol Metabolism in Cancer 
 Epidemiologic studies associate a high-cholesterol diet to an increased risk of 
colorectal cancer, and it has been well-established that cholesterol controls cell 
proliferation, as cholesterol is an integral part of the cellular membrane (Lo Sasso et al., 
2013). Changes in cholesterol homeostasis have been observed in many tumors (Vedin et 
al., 2013). Considering this, it is not surprising that disruption of cholesterol metabolism 
has been associated with the development of cancers, specifically CRC (Lo Sasso et al., 
2013). LXRs regulate cholesterol levels by directing transcriptional programs to decrease 
cholesterol absorption and increase metabolism and excretion of cholesterol, resulting in 
a net cellular decrease of cholesterol. Thus, numerous studies have evaluated the 
relationship between LXR activation and tumorigenesis. Lo Sasso et al. analyzed the 
development of colon cancer in mice that express a constitutively active form of LXRα in 
the intestinal epithelium as well as the development of colon cancer in these mice crossed 
with ApcMin mice (2013). Proliferation and apoptosis of the human cancer cell line HT29 
transfected with Ad VP16hLXRα (an adenoviral vector that expresses LXRα) were 
compared to a control after ligand-induced activation of LXR with GW3965 (Lo Sasso et 
al., 2013). Their data show that LXR activation in HT29 human colon cancer cells 
inhibited the G1 phase of the cell cycle, increased apoptosis, and slowed growth of 
xenograft tumors in mice compared to control (Lo Sasso et al., 2013). The ApcMin  and 
LXRα double-knockout mutant mice developed fewer and smaller intestinal tumors than 
control ApcMin mice (Lo Sasso et al., 2013). These results suggest LXR activation 
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protects against intestinal tumorigenesis, and provide an impetus for further study of the 
role of this nuclear receptor in CRC development and progression.  
 Vedin et al. further investigated the anti-proliferative mechanism of LXRs in the 
colon. Their study of human colorectal adenocarcinoma cell lines Colo205 and HCT116 
found that activation of both isoforms of LXR, α and β, decreased proliferation of these 
cancer cells and observed increased expression of proliferation markers in LXRαβ-/- mice 
(Vedin et al., 2013). In addition, wild-type mice given the GW3965 LXR agonist showed 
a significant reduction of Ki67, a proliferation marker (Vedin et al., 2013). Their data 
show that the molecular mechanism underlying the anti-proliferative functions of LXRs 
is mediated by the ability of LXRs to induce negative cell cycle regulator expression and 
reduce positive cell cycle regulator expression (Vedin et al., 2013). They also found that 
activation of LXRs led to hypo-phosphorylation of the Rb protein, and important CRC 
tumor suppressor protein known to be dysregulated in many cancers (Vedin et al., 2013). 
These results further confirm the anti-proliferative role of LXRs in the colon, and suggest 
the mechanism of this suppression is by direct regulation of cell cycle.  
 As previously discussed in this thesis, β-catenin is a key mediator of the canonical 
Wnt pathway, which regulates cellular renewal of the intestinal epithelium. To further 
study the association between liver X receptors and colon carcinogenesis, Uno et al. 
evaluated the effects of LXR activation on β-catenin (2009). Their data show LXR 
activation decreased mRNA levels of β-catenin transcriptional targets MYC, MMP7, and 
BMP4, suggesting LXR activation suppresses the activation activity of β-catenin (Uno et 
al., 2009). This data suggests a molecular link between dietary lipid signaling and 
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intestinal proliferation pathways, providing a possible explanation for the epidemiologic 
observation that diet affects colon cancer development (Uno et al., 2009). Because diet is 
a relatively simple thing to change, it is of interest to further investigate this as a possible 
CRC prevention or treatment measure. 
 The accumulating evidence that supports the involvement of LXRs in cancer by 
regulating cell proliferation in response to cholesterol suggests that these nuclear 
receptors are a possible therapeutic target, as these receptors tend to be inhibited in CRC 
and many other cancers (Gabitova et al., 2013). Cellular receptors are particularly 
attractive targets for cancer therapy because they are activated by specific ligands and 
have distinct ligand binding domains that allow for specific and effective modulation (Lin 
and Gustafsson, 2015). Targeting nuclear receptors has been particularly effective in 
treating breast and prostate cancers, and advances in medicinal chemistry have facilitated 
the development of receptor-selective, full, partial, and inverse agonists for these 
receptors (Lin and Gustafsson, 2015). The structure of LXRs and their respective 
endogenous and synthetic ligands are well-established. Thus, our gap in knowledge is 
how these receptors exert their anti-proliferative effects in colon cancer. Establishing how 
LXR activity is limited will allow for more pre-clinical trials of LXR as an anti-cancer 
therapy target.  
Focus of Thesis 
KCNQ1, a gene which encodes for a voltage-gated ion channel, and CFTR, a gene 
which encodes for an ion channel which promotes chloride and bicarbonate secretion, 
have been identified by genetic studies as murine susceptibility genes for intestinal 
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tumorigenesis (Than et al., 2016; Than et al., 2013; Starr et al., 2009). Mutation of 
KCNQ1 is associated with several human disease syndromes including Jervell and 
Lange-Nielson syndrome, long QT syndrome, iron-deficiency anemia, gastric and 
duodenal hyperplasia, and enhanced risk for type-2 diabetes (Yasuda et al., 2008). 
Similarly, mutation of CFTR is the causal genetic event for cystic fibrosis, a life-
shortening disease that is the most common autosomal recessive disease in Caucasian 
populations. 
Although KCNQ1 and CFTR were identified as a susceptibility genes for colon 
cancer, their roles in disease development are largely unknown. Analysis of human CRC 
patient data show that patients with high KCNQ1 or high CFTR expression have better 
disease-free survival rates compared to patients with low expression of these genes (Than 
et al., 2013; Than et al., 2016). Thus, KCNQ1 and CFTR have an implied role in colon 
cancer development, but functional characterization of this mechanism has not yet been 
established.  
 The goal of this thesis was to determine the tumor suppressive mechanisms of 
KCNQ1 and CFTR. While developing our strategy for determining these mechanisms, we 
considered multiple experimental methods. Although many tissue culture systems have 
been established in efforts to investigate the pathology of colorectal cancer, no long-term 
culture system maintained basic crypt-villus physiology of the intestinal tissue (Sato et 
al., 2009). Considering this, Sato et al. developed the intestinal organoid culture system. 
Intestinal organoids are comprised of isolated intestinal stem cells that recapitulate the 
self-renewal and differentiation capacity of the tissue of origin, thus modeling the stem 
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cell capacity of the tissue they are derived from. Five to six stem cells expressing the 
Lgr5+ marker reside in the base of the crypt and can be isolated from the tissue and other 
differentiated cells by treatment with EDTA, vigorous washes, and differential 
centrifugation. These isolated stem cells can be grown in the absence of a non-epithelial 
cellular niche and self-organize into crypt-villus domains, in which all differentiated cell 
types are present, by undergoing multiple crypt-fission events (Sato et al., 2009). While 
the organoids established by Sato utilize isolated stem cells, organoids can also be grown 
from isolated intestinal crypts, which is the protocol our lab utilizes. Organoids are grown 
in Matrigel, a 3D culture medium rich in laminin, to mimic the environment of the crypt 
base (Sato et al., 2009). To provide the necessary growth requirements for the stem cells, 
Sato et al. established growth media supplemented with necessary factors to direct stem 
cell proliferation and differentiation. These advancements in culture systems allowed for 
a more simplified study of stem-cell-driven crypt villus biology (Sato et al., 2009).  
 Previous studies by a former member of our lab, Dr. B.L.N Than, utilized 
intestinal organoids to determine the role of KCNQ1 and CFTR in the stem cell 
compartment. Than et al. harvested intestinal organoids from the colons of littermate and 
gender matched Kcnq1 -/- and Cftr -/- mice (2013 and 2016, respectively). Organoid 
growth was monitored and evaluated from days 2-5 post-plating (Than et al., 2016). The 
data showed that loss of Kcnq1 increased the number of colon organoids 3-fold. Than et 
al. found similar tumor suppressive effects in colon organoids derived from Cftr -/- mice, 
in which loss of Cftr enhanced colon organoid growth by 2.3-fold (Than et al. 2016). 
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These results suggest a potential role of Kcnq1and Cftr in regulating the intestinal stem 
cell compartment (Than et al., 2016). 
The specific focus of this thesis was to investigate KCNQ1 and CFTR as 
colorectal cancer tumor suppressors by their role in regulating the stem cell compartment. 
To inform our experimental aims and hypotheses, we began by confirming the expression 
of KCNQ1 in crypts of the intestinal epithelium, where the stem cells reside. We then 
used Illumina high-throughput sequencing technology to analyze mRNA levels in 
organoids derived from KCNQ1 WT and KO mice. This data allowed us to identify 
candidate biological pathways and processes that were altered due to loss of KCNQ1, and 
to design functional experiments to further confirm and explore these differences and 
their effects on the stem cell compartment. We used reverse-transcriptase quantitative 
PCR to analyze gene expression changes in Kcnq1-/-  and Cftr -/-  organoids in response to 
activation of specific biological pathways. From projects like this, it is our goal to 
characterize the tumor suppressive mechanism of KCNQ1 and CFTR on the intestinal 
stem cell compartment. This understanding could lead to potential development of 
biomarkers for colorectal cancer as well as therapeutic targets.  
 
Materials and Methods 
Animal Models 
 C57BL/6-Kcnq1 knockout mice were obtained from Dr. Karl Pfeifer (NIH). 
Kcnq1 was inactivated in the germline of mice by insertion of a neomycin cassette into 
exon 2, the first common exon to all isoforms (Casimiro et al., 2000). C57BL/6-Cftrfl10 
mice were obtained from Drs. Mitchell Drumm & Craig Hodges (CWRU). LoxP sites 
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flanking exon 10 of the Cftr gene were inserted, and Cftr was conditionally inactivated by 
Cre recombinase in the intestinal epithelium by control of the Villin promoter (Hodges et 
al., 2008). All mice used in this study were housed per IACUC protocols and standards. 
Because CFTR knockout mice accumulate viscous mucus in their digestive organs, a 
commercially available osmotic laxative was added to the drinking water of these mice 
(Gavilyte-C, Gavis Pharmaceuticals, Somerset, NJ, USA). All animal experiments were 
conducted per protocol as approved by the University of Minnesota IACUC.  
Organoid Culture: Harvesting and Plating 
 Littermate mice of approximately 8-14 weeks of age were selected in genotypic 
pairs (wildtype and knockout) for obtaining organoids. Mice were euthanized in a CO2 
chamber for 4-5 minutes, and the small intestine was removed and washed briefly in ice-
cold 1X PBS. The small intestine was cut longitudinally along its entire length and 
scraped gently with a clean microscope slide to remove villi. The small intestine was then 
washed 2-3 times vigorously in petri dishes containing ice-cold 1X PBS. After washing, 
the small intestine was cut using a sterile razorblade into 2-3 mm pieces. These intestinal 
pieces were then transferred to a 50-mL conical tube containing approximately 10 ml ice-
cold PBS. A plastic pipet tip was coated with FBS and used along with a Pipet-Aid to 
wash the intestinal pieces by resuspension in 10 ml ice-cold PBS. The pieces were 
brought into the tip and ejected out near the bottom of the conical tube, disturbing the 
intestinal pieces to remove cellular debris. This was repeated three times, and the pieces 
were allowed to settle before removing and discarding the supernatant. The amount of 
washes with 10 ml ice-cold PBS varies between each organoid prep. In general, intestinal 
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pieces were washed until the supernatant no longer appeared cloudy (8-10 washes for 
small intestine). After the last wash, intestinal pieces were resuspended in 25 ml ice-cold 
chelation buffer (1X PBS, 43.4 mM sucrose, 54.9 mM D-sorbitol, and mQ H2O) and 
EDTA (2.5 x 10-3 M). The intestinal pieces were incubated in this chelation buffer and 
EDTA solution for 30 minutes on a rotating spinner at 4°C. After incubation, the 
supernatant containing EDTA was removed, and the intestinal pieces were washed with 
approximately 10 ml of ice-cold chelation buffer, pipetting the pieces up and down as 
described above. 10 µL of the supernatant was checked under the microscope for the 
presence of crypts after each new wash. Supernatants that contained crypts were pooled 
to a separate tube. The number of washes pooled varies between crypt preparations, but is 
generally between the second and tenth washes, and washes are pooled until no more 
crypts are seen in the supernatant.  
 The 50 mL conical tube with the pooled supernatants containing crypts was spun 
at 300 x g at 4°C for 5 minutes. The supernatant was removed, as the pellet contains the 
crypts. The pellet was resuspended in 10 ml ice-cold chelation buffer and filtered through 
a 70 µm cell strainer into a clean 50 mL conical tube. The pass-through was transferred to 
a 15 mL conical tube and spun at 200 x g for 4 minutes to pellet the crypts, the 
supernatant was discarded, and repeated 3-4 times. The pellet was resuspended in 10 ml 
ADF and a 20 µL aliquot was counted using a hemocytometer. The volume of the 
aliquots for plating was calculated by multiplying the number of crypts counted in a 20 
µL aliquot by the total volume of ADF used to resuspend the crypt pellet in. Then, the 
number of crypts desired per well is divided by the concentration of crypts in the 
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suspsension to give the volume of crypts to and this resultant volume was aliquoted. The 
crypts resuspended in ADF were then aliquoted to 15 mL conical tubes and spun down to 
pellet. The pellet was resuspended in 200 µL Matrigel (growth factor reduced, phenol red 
free; BD Biosciences) and plated to 6 wells of a 24 well cell culture plate (approximately 
1000 crypts per 30 µL of Matrigel per well). Once the Matrigel has solidified, 500 µL of 
ADF media (supplemented with Hepes, L-Glutamine, RSPO1, EGF, Noggin, B27, N2, 
N-Acetylcysteine, and primocin) was added to each well. Organoids were incubated at 
37°C and 5% CO2.  
  
Organoid Culture: Passaging 
 Harvested organoids were passaged every six to seven days to maintain a 
consistent line. To each well of organoids, 500 µL Cell Recovery Solution (Corning, Cat. 
No. 354253) was added and plates were incubated at 4°C for one hour. The bottom of 
each well was gently scraped using a P1000 pipette, and the organoids suspended in Cell 
Recovery Solution were pooled together (per treatment and/or genotype) and diluted to 
approximately ten ml with ADF+Hepes+L-Glut. These pooled organoids were spun at 
100 x g at 8°C for five minutes. The pellet is resuspended in approximately five ml of 
ADF+Hepes+L-Glut and the organoids were further disrupted by repeated pipetting up 
and down using a 2-mL plastic pipet tip with an additional unfiltered pipet tip stuck on 
the end. The disrupted organoids were spun again at 200 x g at 8°C for five minutes, and 
the resulting pellet was resuspended in 50 µL complete organoid media. Matrigel (100 
µL) was added to this solution of media and organoids and the mix was plated evenly 
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across six wells of a 24-well plate. Organoids were plated and cultured per the previous 
section. 
 
Organoid Culture: Treatment 
 Organoids were treated with either the LXR agonist GW3965 (Sigma, cat. no. 
G6295) or Thapsigargin, both at a final concentration of 1 µM. To prepare, the organoid 
growth media was changed the day prior to treatment. A 1 mM stock of GW3965 or 
Thapsigargin was diluted 1:4 in ADF. Two µL of this dilution was added to each well of 
organoids to be treated and left overnight before harvesting of RNA. As a control, an 
equal volume of 0.05% DMSO was added to each well.  
 
MTT Assay 
 The cell viability of organoids derived from Kcnq1 and Cftr WT and KO mice 
was measured using an MTT assay. This colorimetric assay measures the activity of 
cellular enzymes that convert MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) to a purple formazan product by measuring the absorbance of the solution. The 
amount of signal generated is dependent on the concentration of MTT, the length of the 
incubation period, the number of viable cells, and metabolic activity of the cells being 
analyzed (Riss et al., 2013). Organoids were plated in a 96-well plate for the MTT assay. 
To recover the organoids for passaging, the Matrigel was mechanically disrupted by 
vigorous pipetting, washed with ADF, and centrifuged at high speeds (800-1,000 rpm for 
four minutes). The organoids were pooled together and then serially diluted from the 
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pooled sample, which served as the undiluted “stock.” The tubes were prepared as 
follows: the “100” sample contained 2 mL “stock”; the “75” sample contained 1.5 mL 
“stock” and 0.5 mL ADF; the “50” sample contained 1 mL “stock” and 1 mL ADF; the 
“25” sample contained 0.5 mL “stock” and 1.5 mL ADF. These diluted tubes were spun 
at 800-1,000 rpm for an additional four minutes to pellet the organoids. The pellet was 
resuspended in 100 µL Matrigel and plated to a pre-warmed 96-well plate, approximately 
one drop of the Matrigel and organoid suspension per well. An additional row of wells 
were plated with Matrigel and no organoids as a control. Once the Matrigel had 
solidified, 100 µL complete crypt culture media was added to each well, and the 96-well 
plate was incubated at 37°C and 5% CO2. 
 The organoids grew in the 96-well plate for three days before the addition of the 
MTT reagent at 500 µg/mL per well (Roche, Version 18, cat. no. 11-465-007-001). The 
addition of MTT was followed by an incubation period of two to three hours at 37°C and 
5% CO2. To solubilize the Matrigel, the media and MTT was aspirated using a Pasteur 
pipet and 20 µL SDS was added per well and incubated for an additional two hours at 
37°C and 5% CO2.  To solubilize reduced MTT, 100 µL DMSO was added per well 
followed by a one hour incubation at 37°C. The OD was measured on a microplate reader 
at 562nM. Sample absorbencies were normalized using the absorbencies measured from 
the control wells. Normalized measured absorbencies from WT and KO wells were 
compared by their respective dilution (100, 75, 50, and 25) to determine differences in 
the MTT signal between samples. 
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RNA Isolation 
 RNA was isolated from intestinal organoids approximately 4 days post-plating. 
The Qiagen RNEasy Mini Kit (Cat. No. 74104) was used per the manufacturer’s 
protocol, with the following modifications. Media was removed from the organoids using 
a sterile glass pipet attached to a vacuum. Matrigel was dissolved by adding 500 µL Cell 
Recovery Solution (Corning, Cat. No. 354253) and incubated at 4°C for one hour. Once 
dissolved, three to six wells were pooled in 15 mL conical tubes and filled with ADF, 
then spun at 200 x g for five minutes at 4°C. The supernatant was discarded and samples 
were pooled together, resuspended in approximately 15 ml ADF, and spun again at 200 x 
g for 5 minutes at 4°C. After the samples were pooled, the supernatant was removed and 
the pellet was resuspended in 175 µL RLN (supplemented with RNAsin and 1M DTT) 
and incubated on ice for five minutes. The samples were spun at 300 x g for two minutes 
at 4°C, and the supernatant was transferred to an RNA-free Eppendorf tube.  The rest of 
the procedure followed the manufacturer’s protocol (Qiagen RNEasy Mini Kit, Cat. No. 
74104). The final concentration of RNA was measured on a NanoDrop in ng/µL. 
 
Immunohistochemistry 
 Expression and localization of KCNQ1 was analyzed by immunohistochemistry 
of mouse tissue. Small intestine and colon were harvested from littermate mice and 
washed in PBS to remove excess fecal matter. The tissue was sprayed with 70% ethanol 
and was fixed overnight in formalin. Fixed tissues were dehydrated by an automated 
Tissue-Tek VIP processor and embedded in paraffin blocks using the Leica EG1160. 
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Paraffin embedded tissues were sectioned at five microns with a Reichert-Jung 2030 
microtome and were mounted to charged microscope slides. The mounted slides were 
dried in a 60°C oven for 30 minutes and subsequently deparaffinized in xylene, followed 
by a rehydration process with a series of ethanol washes. Antigen retrieval was performed 
with rodent decloaker in an 85°C water bath for 40 minutes. The primary antibody 
KCNQ1 (H-130, Santa Cruz cat. no. sc-20816) was used at a concentration of 1:150 and 
incubated overnight at 4°C. Bound antibodies were detected using goat anti-rabbit IgG 
Alexa Fluor 568 (1:500, Fisher Scientific cat. no. A11036) and Prolong Diamond 
Antifade DAPI (Life Technologies, cat. no. P36966). DAB Chromogen (Biocare Medical 
LLC cat. no. DB801R) was also used to detect bound antibodies. Image acquisition was 
performed using a Zeiss LZM710 laser scanning confocal microscope. 
 
Illumina Next-Generation RNA Sequencing 
 RNA was isolated from CFTR and KCNQ1 WT and KO organoids as previously 
described. For RNA quality control, the protein concentration was determined using a 
Nanodrop and one µg of each sample was sent to the University of Minnesota 
Biomedical Genomics Center (Minneapolis, MN) to analyze distinct 28s and 18s bands. 
These ribosomal RNA bands are a visual way to analyze the quality of total RNA, and 
crisp bands indicate intact RNA, as well as intact mRNA, which cannot be visualized 
with electrophoresis. 2,000 ng of RNA per well (concentration of 100 ng/µL) of three 
paired samples (WT and KO) per genotype (CFTR and KCNQ1) were sent to the 
University of Minnesota Biomedical Genomics Center (Minneapolis, MN) for Illumina 
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Next-Generation RNA sequencing following the UMGC’s submission instructions. 
Illumina Next-Generation RNA sequencing is a high-throughput sequencing system that 
produces between 300 million - 2 billion sequence reads per run of lengths between 50-
500 bp. Next-Generation RNA sequencing uses mRNA fragments to produce cDNA 
templates which undergo short-read sequencing. These sequences are then aligned to a 
reference genome sequence to determine relative expression levels of genes in the 
experimental sample. We used the high-throughput raw expression data we obtained from 
this analysis as a dataset for Gene Set Enrichment Analysis (Broad Institute) to determine 
gene sets that were enriched (comparatively high expression) or depleted (comparatively 
low expression) between the two sets of organoids, KCNQ1 or CFTR WT and KO.  
 
Reverse-Transcriptase Quantitative Polymerase Chain Reaction  
 Target gene expression was analyzed and compared between KCNQ1 and CFTR 
WT and KO organoids by reverse-transcriptase quantitative polymerase chain reaction 
(RT-qPCR). RT-qPCR monitors the amplification of a targeted DNA molecule during the 
polymerase chain reaction in real time using non-specific fluorescent dyes that 
incorporate into double-stranded DNA. Absolute quantification can be used to quantify 
the copy number of specific nucleic acids in a sample by comparison with DNA 
standards using a calibration curve. Gene standards were created by first reverse-
transcribing 1.5 µg mouse colon RNA using Qiagen Omniscript RT Kit (cat. no. 205113) 
and gene-specific primers. The standard cDNA was amplified using Qiagen HotStarTaq 
Master Mix Kit (cat. no.203443) and purified using the Qiagen MinElute PCR 
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Purification Kit (cat. no. 28004). 0.5-1.5 µg RNA isolated from CFTR and KCNQ1 WT 
and KO organoids (as previously described) was reverse-transcribed to cDNA using 
Qiagen Omniscript RT Kit (cat. no. 205113) and random 9 primers. The organoid sample 
cDNA was diluted 1:10 for analysis of specific target genes and 1:100 for analysis of 18S 
standard genes. 18S standard curves were amplified from a dilution range of 1e8 
copies/µL to 1e3 copies/µL. All samples and standards were plated in duplicate on a 96-
well plate using a Roche Light Cycler480 Real-Time PCR Instrument with the following 
cycle parameters: pre-incubation- one cycle, 95°C for five minutes; amplification- 45 
cycles, 95°C for five seconds, 60°C for five seconds, and 72°C for ten seconds; melt 
curve- one cycle, 95°C for five seconds, 65°C for one minute, and 97°C continuous; and 
cooling- one cycle at 40°C for 30 seconds. To perform concentration analysis, the 
LightCycler 480 Real-Time PCR Instrument was used. Because both quantity and quality 
of mRNA may vary from sample to sample, an internal control was used for analysis. 
18S is a ribosomal subunit expected to be expressed ubiquitously and relatively 
uniformly across samples. Thus, it is an accurate way to normalize target gene expression 
between experimental samples to controls and correct sample variability. Standard curves 
were calculated for both 18S and target genes using mRNA samples of known 
concentrations. These standard curves serve as a reference standard for extrapolating 
quantitative information for sample mRNA targets of unknown concentration. 
 
Gene Set Enrichment Analyses 
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 Transcriptomic analysis was performed using Gene Set Enrichment Analysis 
(GSEA) software from the Broad Institute. GSEA is a statistical method to identify 
groups of genes (gene sets) that are significantly enriched or depleted in a given set of 
gene expression data (datasets). This analysis provides a functional profile of the 
experimental dataset to better evaluate the underlying biological processes that may be 
altered due to phenotypic differences between the samples. The datasets used for analysis 
were from previously published studies of primary human tumor samples analyzed by 
Affymetrix Human Genome U133 Plus 2.0 Array and can be found under GEO accession 
numbers: GSE33113, GSE14333, and GSE13294. The datasets were sorted continuously 
for KCNQ1 low to high expression or sorted continuously for CFTR low to high 
expression and the Pearson correlation coefficient was the statistical analysis used. The 
hallmark signature gene set was found in the molecular signatures database. The genes in 
this gene set were determined based on overlaps in other molecular signatures database 
gene sets and retaining genes that display coordinate expression. The parameters of the 
GSEA for all three dataset analyses were weighted enrichment statistic and Pearson 
correlation coefficient as the metric for ranking genes. The top four gene sets that were 
enriched in all three tumor datasets were identified. 
 
 Results 
Kcnq1 is expressed at the base of the colonic crypt 
The goal of this study was to evaluate our working model of KCNQ1 tumor 
suppression by utilizing gene expression analysis, both targeted and global, as well as 
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functional assays. We hypothesized that the loss of KCNQ1 causes oncogenic changes to 
the stem cell compartment of the intestinal epithelium. To begin, we needed to confirm 
Kcnq1 is expressed in the stem cell compartment of murine colon. Immunohistochemical 
analysis for the protein showed the highest expression near the base of the crypt (Figure 
1). The signal diffuses as it progresses up the crypt, and is virtually absent near the top of 
the crypt. This data confirms that Kcnq1 is expressed in the base of the crypt 
compartment of murine colonic tissue, where the stem cells are known to reside. A 
similar immunohistochemical analysis was published by Preston et al. (2011) and was 
used as a reference for developing this protocol. These results confirm the results of 
Preston et al. (2011).  
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Figure 1. Kcnq1 is expressed in the base of the crypt. Kcnq1 staining on representative 
colonic sections of animals of indicated genotypes. Magnification 20X.  
MTT Analysis of Organoids 
 Organoids harvested from Kcnq1 KO and WT mice as well as Cftr WT and KO 
mice were analyzed for differences in cell viability using the MTT assay. These ratios 
allow for comparison of the KO MTT signal at all four dilutions (100, 75, 50, 25) to the 
WT 100 MTT signal as the baseline of 1. Thus, any increase or decrease of the MTT 
signal in the KO organoids is in comparison to the WT 100 MTT signal value. The 
organoids derived from Kcnq1 KO mice have a slightly higher MTT signal at all four 
relative dilutions, although a two-way ANOVA analysis determined this difference is not 
statistically significant at p ≤ 0.05 (Figure 2a). Similarly, organoids derived from Cftr KO 
mice have a slightly higher MTT signal at all four relative dilutions (Figure 2b). Analysis 
of these values with a two-way ANOVA determined this difference in MTT signal is also 
not statistically significant (p ≤ 0.05).  
 
Figure 2. MTT Cell Viability Assay of Organoids. a. Kcnq1 KO organoids have a slightly 
higher MTT signal compared to WT organoids. b. Cftr KO organoids have a slightly 
higher MTT signal compared to WT organoids.  

Organoid RNA Quality Assessment 
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Once we had confirmed the expression of Kcnq1 in the stem cell compartment of 
the intestinal crypt, we proceeded to organoid studies. Organoid RNA was harvested 
from pairs of Kcnq1 +/+ and Kcnq1 -/- littermate mice for Illumina Next-Generation RNA 
Sequencing by the University of Minnesota Genomic Center after analysis of RNA 
quality. I harvested and cultured the organoids with help from Kyle Anderson, and Kyle 
Anderson isolated organoid RNA and also organized and prepared the RNA samples for 
sequencing. Figure 3 shows two distinct ribosomal RNA bands at 18s and 28s, which 
indicate total RNA derived from organoid samples was overall intact.  
 
Figure 3. Organoid RNA quality assessment. All organoid RNA pairs passed quality 
control analysis and display two solid bands representing 18s (2,000 bp) and 28s (4,000-
6,000 bp) ribosomal RNA. 
 
Illumina Next-Generation RNA Sequencing of Organoid RNA 
 Illumina Next-Generation RNA Sequencing was performed on Kcnq1 +/+ and 
Kcnq1 -/- organoid RNA by the University of Minnesota Genomics Center. Three Kcnq1 
WT and KO organoid RNA pairs were analyzed. Hi-Seq 2500 High-Output was run on 
these samples and detected over 21,000 different transcripts.  
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Gene Set Enrichment Analysis of Organoid RNA Sequencing Data 
 RNA expression data from three Kcnq1 +/+ and -/- littermate paired mice was 
analyzed using GSEA software from the Broad Institute. GSEA is a useful tool for 
interpreting genome-wide expression profiles because it utilizes gene sets, or groups of 
genes that share common biological function (Subramanian et al., 2005). Based on 
previous GSEA analyses of this dataset that found the unfolded protein response (UPR) 
was enriched in the Kcnq1 KO organoids, we then further analyzed this enrichment. The 
UPR gene set used in this analysis was previously published by Han et al. (2009). GSEA 
determined upregulation of the UPR gene set in Kcnq1 WT organoids and 
downregulation of the UPR gene set in Kcnq1 KO organoids by comparing these as two 
distinct phenotypes (Figure 4). Although one representative enrichment plot is shown 
here, all unfolded protein response gene sets ran also showed similar enrichment in the 
Kcnq1 KO phenotype. This specific gene set, published in Han et al. 2009, includes 
genes involved in the IRE1α arm of the UPR that were upregulated 2-fold upon 
activation of the UPR. This data suggests that the loss of Kcnq1 affects either the 
activation of the unfolded protein response in organoids (by altering expression of genes 
directly involved in the UPR) or affects the response of these organoids to activation of 
the UPR via downstream pathways that result because of UPR activation.  
  43 
 
Figure 4. UPR Gene Set Enrichment Plot. The unfolded protein response gene set is 
enriched in the Kcnq1 WT organoids compared to the Kcnq1 KO organoids. The 
enrichment plot shows a profile of the running enrichment score and positions of gene set 
members on the rank ordered list. 
 
Gene Set Enrichment Analysis of Primary Tumor RNA Sequencing Data 
 RNA expression data (HG-U133_Plus_2 Affymetrix Human Genome U133 Plus 
2.0 Array) from three public GEO Datasets was analyzed using GSEA. The mRNA used 
in each dataset was derived from the following samples: dataset GSE33113 consisted of 
primary tumor resections from 90 Stage II CRC patients and matching normal colon 
tissue from 6 of these patients; dataset GSE14333 consisted of 290 primary colorectal 
tumor samples; dataset GSE13294 consisted of 155 primary colorectal tumor samples. 
The datasets were sorted continuously, either as KCNQ1 low to high expression, or CFTR 
low to high expression. The hallmarks of cancer gene set (Molecular Signatures Database 
(MSigDB), Broad Institute, h.all.v6.0.symbols) was run against these datasets, and the 
negative Pearson correlation coefficient statistical test was used to determine the top four 
gene sets enriched in the knockout phenotype in all three datasets. The hallmarks of 
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cancer gene set is a collection of gene sets that summarize and represent the biological 
state of cancer and display coherent expression. These gene sets were generated by a 
computational methodology based on identifying overlaps between gene sets in other 
MSigDB collections and retaining genes that display coordinate expression (Subramanian 
et al., 2005).  
Gene Set Enrichment Analysis of Tumor Data- KCNQ1 
 To gain insight into the biological pathways affected by the loss of KCNQ1 in 
humans, we used GSEA to determine gene sets that were enriched or depleted in human 
tumor mRNA. The three primary tumor datasets were sorted continuously for low to high 
KCNQ1 expression. GSEA was performed on these datasets for the hallmarks of cancer 
gene set. Table 1 shows the top four gene sets that were enriched in the KCNQ1 low 
phenotype in all three datasets. The top gene sets were selected by the false discovery rate 
(FDR) cutoff of 0.25. The epithelial mesenchymal transition gene set was enriched at a 
statistically significant level in the KCNQ1 low phenotype of all three tumor datasets. 
The inflammatory response gene set was enriched at a statistically significant level in the 
KCNQ1 low phenotype of two tumor datasets (14333 and 13294), although it was not 
found to be enriched in the tumor dataset 33113. The allograft rejection and interferon 
gamma response gene sets were enriched at a statistically significant level in all three 
tumor datasets. 
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Table 1. Gene sets enriched in the KCNQ1 low expressing tumor samples. False 
discovery rate (FDR) and the normalized enrichment score (NES) are shown for each 
dataset and gene set. 
 
Gene Set Enrichment Analysis of Kcnq1 +/+ and -/- Organoids 
 We performed GSEA on Kcnq1 +/+ and -/- organoid mRNA expression data to 
determine which gene sets were enriched or depleted due to loss of Kcnq1. The enriched 
or depleted gene sets informed us of what associated biological pathways may be affected 
by the loss of Kcnq1, as well as whether these pathways affect the stem cell compartment 
of the tissue. By comparing the enriched gene sets to the gene sets determined as enriched 
in the KCNQ1 low tumor data, we can compare tumor tissue gene expression changes 
and stem cell compartment gene expression changes due to loss of Kcnq1. This analysis 
was performed differently from the previous one (Table 1), as the phenotype was not 
continuous, but was set as two distinct phenotypes (Kcnq1 +/+ and -/-).  
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 Table 2 shows the top four enriched gene sets in the Kcnq1 -/- organoid phenotype. 
The inflammatory response and epithelial mesenchymal transition gene sets were 
enriched in Kcnq1 -/- organoids at a statistically significant level (FDR of 0.004 and 
0.020, respectively). These gene sets were also found to be enriched in the KCNQ1 low 
expressing tumor sample phenotype. The cholesterol homeostasis and IL6 JAK-STAT3 
signaling pathway gene sets were also enriched at a statistically significant level (FDR of 
0.027 and 0.027, respectively), but were not found to be enriched in the tumor datasets.  
 Generally, these enriched gene sets are interesting and important because of the 
well-researched and established role of inflammation in cancer development and 
progression. It is also important to note than some of the enriched processes in tumors are 
also enriched in organoids, supporting intestinal organoids as a sufficient experimental 
model. 
 
Table 2. Gene sets enriched in the Kcnq1 -/- organoids. False discovery rate (FDR) and 
the normalized enrichment score (NES) are shown for each gene set. 
 
Gene Set Enrichment Analysis of Tumor Data- CFTR 
 To gain insight to the biological pathways affected by the loss of CFTR in 
humans, we used GSEA to determine gene sets that were enriched or depleted in human 
tumor mRNA. The three primary tumor datasets were sorted continuously for low to high 
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CFTR expression. GSEA was performed on these datasets for the hallmarks of cancer 
gene set. Table 3 shows the top four gene sets that were enriched in the CFTR low 
phenotype in all three datasets. The gene sets were considered significant by the false 
discovery rate cutoff of 0.25. The epithelial mesenchymal transition gene set was 
enriched in the CFTR low phenotype of all three tumor datasets, but not at a statistically 
significant level. The inflammatory response gene set was enriched at a statistically 
significant level in the CFTR low phenotype of two tumor datasets (33113 and 13294), 
although it was not found to be enriched in the tumor dataset 14333. The tumor necrosis 
factor (TNF) signaling via NF-κB gene set was enriched in the CFTR low phenotype of 
two of the tumor datasets (14333 and 13294) but was not significantly enriched in 33113. 
The angiogenesis gene set was enriched at a statistically significant level in all three 
tumor datasets. 
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Table 3. Gene sets enriched in the CFTR low expressing tumor samples. False discovery 
rate (FDR) and the normalized enrichment score (NES) are shown for each dataset and 
gene set. 
 
 
RT-qPCR Analysis of Kcnq1 +/+ and Kcnq1 -/- Organoids 
 Organoids were harvested and cultured from pairs of Kcnq1 +/+ and Kcnq1 -/- 
mice, and mRNA was isolated from these cultures. RT-qPCR was performed on this 
RNA to analyze gene expression changes of target genes in the WT and KO organoids. 
Previous GSEA data showed that in Kcnq1-deficient tissue expression of the unfolded 
protein response (UPR) gene set is depleted. To investigate this further, we treated one 
pair of Kcnq1 +/+ and Kcnq1 -/-  organoids with Thapsigargin, an inducer of the UPR. RNA 
was isolated from these organoids for analysis by RT-qPCR. The target gene activating 
transcription factor 4 (Atf4) was analyzed in both treated and untreated Kcnq1 +/+ and 
Kcnq1 -/-  organoids (Figure 5). Atf4 is a regulatory element that increases protein folding, 
transport, and ER-associated protein degradation, while attenuating protein synthesis 
(Wang and Kaufman, 2014). The basal expression level of Atf4 in Kcnq1 -/- organoids is 
slightly higher than the basal expression of this gene in Kcnq1 +/+ organoids. However, 
the expression level of Atf4 is slightly lower in Kcnq1 -/-  organoids after treatment with 
Thapsigargin and induction of the unfolded protein response. An unpaired t-test was run 
to analyze the statistical significance of these data, as well as the entirety of the RT-qPCR 
data in this thesis (unpaired t-test, all samples assumed to be sampled from populations 
with the same standard deviation, α=0.05 for multiple comparisons using the Holm-Sidak 
method). The difference between the control expression levels is not statistically 
significant at p ≤ 0.05 (p=0.0781). However, the WT organoids express Atf4 in response 
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to treatment with Thapsigargin at a significantly higher amount than in Kcnq1 -/-  
organoids after treatment with Thapsigargin at p ≤ 0.05 (p=0.0056). This data suggests 
loss of Kcnq1 in organoids has an effect on the expression of Atf4 in response to 
induction of the unfolded protein response, as it is clear the organoids both respond to 
treatment. To confirm these results, more replicates should be tested. 
 
Figure 5. Expression of Atf4 in Kcnq1 +/+ and Kcnq1 -/-  organoids treated with 
Thapsigargin. The basal level of Atf4 expression is slightly increased in Kcnq1 -/-  
organoids compared to Kcnq1 +/+ organoids. Kcnq1 -/-  have a decreased response to UPR 
induction by treatment with Thapsigargin compared to Kcnq1 +/+ organoids. The standard 
error for technical replicates is shown by the error bars. 
 
 In addition, expression of heat shock protein A member 5 (Hspa5) was analyzed 
in Kcnq1 +/+ and Kcnq1 -/-  organoids treated with Thapsigargin as well as in untreated 
controls (Figure 6). Hspa5 encodes the protein endoplasmic reticulum luminal glucose-
regulated protein 78 (GRP78), which functions as an unfolded protein response (UPR) 
signaling regulator by binding to and maintaining ER stress sensors PERK, ATF6, and 
IRE1. The basal expression of Hspa5 in both the Kcnq1 +/+ and Kcnq1 -/-  organoids is 
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quite low, and although the Kcnq1 -/-  organoids have a slightly higher expression level, 
this difference is not significant p ≤ 0.05 (p=0.3947). After treatment with Thapsigargin, 
the expression of Hspa5 drastically increases in both the Kcnq1 +/+ and Kcnq1 -/-  
organoids. However, like the expression of Atf4, the expression level of Hspa5 is 
significantly lower in Kcnq1 -/-  organoids after induction of the UPR at p ≤ 0.05 
(p=0.0362). This data suggests loss of Kcnq1 in organoids has an effect either on the 
expression of Hspa5 in response to induction of the unfolded protein response, or on the 
response of organoids to this treatment. This experiment was performed using only one 
biological replicate. More replicates must be obtained and evaluated to confirm or refute 
these results. 
 
Figure 6. Expression of Hspa5 in Kcnq1 +/+ and Kcnq1 -/-  organoids treated with 
Thapsigargin. The basal level of Hspa5 expression is slightly increased in Kcnq1 -/-  
organoids compared to Kcnq1 +/+ organoids. Kcnq1 -/- organoids have a decreased 
response to UPR induction by treatment with Thapsigargin compared to Kcnq1 +/+ 
organoids. The standard error for technical replicates is shown by the error bars. 
 
 In addition to analyzing expression of UPR target genes in Kcnq1 +/+ and Kcnq1  -
/-  organoids treated with Thapsigargin, we analyzed two intestinal stem cell signature 
genes, Achaete-Scute Family BHLH Transcription Factor 2 (Ascl2) and Leucine-rich 
repeat-containing G-protein coupled receptor 5 (Lgr5). Previous data show induction of 
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the UPR by Thapsigargin suppresses the expression of stem cell signature genes and UPR 
genes are highly expressed in differentiated cells, such as transit amplifying cells 
(Heijmans et al., 2013).  
 Ascl2 is an intestinal stem cell marker gene that encodes a transcription factor 
whose related pathways include embryonic and pluripotent stem cell differentiation 
pathways and lineage specific markers. Expression of Ascl2 in Kcnq1 +/+ and -/-  organoids 
treated with Thapsigargin was analyzed using RT-qPCR (Figure 7). The data show basal 
expression of Ascl2 is slightly higher in Kcnq1 -/-  organoids compared to Kcnq1 +/+ 
organoids, but this is not a significant difference at p ≤ 0.05 (p=0.0529). The expression 
level of Ascl2 drastically decreased after treatment with Thapsigargin in both Kcnq1 +/+ 
and Kcnq1 -/-  organoids, however, the Kcnq1 -/-  organoids express Ascl2 at a lower level 
after induction of the UPR compared to Kcnq1 +/+ organoids, but this is not a significant 
difference at p ≤ 0.05 (p=0.0723). These data suggest that loss of Kcnq1 in intestinal 
organoids affects the expression of Ascl2 in the basal state as well as the expression of 
Ascl2 in response to treatment with Thapsigargin and induction of the UPR. These results 
were obtained from one biological replicate. More replicates and experiments are needed 
to confirm or refute these results. 
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Figure 7. Expression of Ascl2 in Kcnq1 +/+ and Kcnq1 -/-  organoids treated with 
Thapsigargin. The basal level of Ascl2 expression is slightly increased in Kcnq1 -/-  
organoids compared to Kcnq1 +/+ organoids. Kcnq1 -/-  organoids have a decreased 
response to UPR induction by treatment with Thapsigargin compared to Kcnq1 +/+ 
organoids. The standard error for technical replicates is shown by the error bars. 
 
 The expression levels of intestinal stem cell marker gene Lgr5 showed a similar 
trend (Figure 8). The basal expression level of Lgr5 was higher in Kcnq1 -/-  organoids 
compared to Kcnq1 +/+ organoids, and according to a t-test, this difference is significantly 
different at p ≤ 0.05 (p=0.0347). After treatment with Thapsigargin, the expression of 
Lgr5 in both Kcnq1 -/-  and Kcnq1 +/+ organoids drastically decreases, but the difference 
between Kcnq1 -/-  and Kcnq1 +/+ organoids is not significant at p ≤ 0.05 (p=0.5577). This 
data supports previous studies that show induction of the UPR suppresses the expression 
of intestinal stem cell marker genes, but we cannot conclude there is a difference in this 
suppression due to loss of Kcnq1. This experiment was performed using only one 
biological replicate. More replicates must be obtained and evaluated to confirm or refute 
these results. 
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Figure 8. Expression of Lgr5 in Kcnq1 +/+ and Kcnq1 -/-  organoids treated with 
Thapsigargin. The basal level of Lgr5 expression is slightly increased in Kcnq1 -/-  
organoids compared to Kcnq1 +/+ organoids. The expression of Lgr5 in response to UPR 
induction by treatment with Thapsigargin is virtually absent in both Kcnq1 +/+ and Kcnq1 
-/-  organoids. The standard error for technical replicates are shown by the error bars. 
 
RT-qPCR Analysis of Cftr+/+ and Cftr -/- Organoids 
 Reverse-transcriptase quantitative polymerase chain reaction (RT-qPCR) was 
used to analyze differences in gene expression between organoids derived from the 
intestinal tissue of littermate mice, whose genotype was either wildtype or deficient for 
Cftr. Ingenuity Pathway Analysis (IPA) of CFTR normal and deficient tissue performed 
by previous members of our lab revealed that the LXR/RXR pathway was inhibited in 
CFTR-deficient tissue compared to normal tissue. To further analyze this inhibition, we 
treated one pair of Cftr+/+ and Cftr -/- organoids with the LXR agonist GW3965 and 
analyzed gene expression of genes associated with this pathway, stearoyl-CoA 
desaturase-1 (Scd1) and aldehyde dehydrogenase 1 family, member A1 (Aldh1a1).  
 Scd1 encodes an enzyme that produces monounsaturated fatty acids, which serve 
as substrates for various kinds of lipids involved in a multitude of biological processes. 
The basal expression level of Scd1 is quite low in both Cftr+/+ and Cftr -/- organoids, but 
significantly higher in Cftr+/+ organoids at p ≤ 0.05 (p=0.0086, Figure 9). After treatment 
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with LXR agonist GW3965, expression of Scd1increases in both Cftr+/+ and Cftr -/- 
organoids, however, the expression level is significantly higher in Cftr+/+ organoids at p ≤ 
0.05 (p=0.0125). What should be noted about this data is that the ratio of the change in 
expression of Scd1 before and after treatment with GW3965 is greater in Cftr+/+ 
organoids compared to Cftr -/- organoids. This suggests that loss of Cftr may have an 
effect on the expression of Scd1 in response to treatment with LXR agonist in organoids. 
Only two biological replicates were evaluated in this experiment. More replicates are 
needed to confirm or refute this result. 
   
 
Figure 9. Expression of Scd1 in Cftr +/+ and Cftr -/-  organoids treated with GW3965. The 
basal level of Scd1 expression is increased in Cftr +/+ organoids compared to Cftr  -/- 
organoids. The expression of Scd1 in response to LXR/RXR pathway agonist GW3965 is 
stronger in Cftr +/+ organoids than Cftr -/-  organoids. The standard error for technical 
replicates are shown by the error bars. 
 
 Another gene we tested for differences in expression levels between Cftr +/+ and 
Cftr -/- organoids is Aldh1a1. Aldh1a1 is the second major enzyme in the oxidative 
pathway of alcohol metabolism and is considered an intestinal stem cell signature gene. 
Although there is a slight difference between the basal expression level of Aldh1a1 in 
Cftr +/+ and Cftr -/- organoids, it was not significant at p ≤ 0.05 (p=0.5258). The expression 
in response to treatment with LXR agonist GW3965 is drastically different (Figure 10). 
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Cftr -/- organoids respond to GW3965 by increasing the expression of Aldh1a1, however, 
this response is less than Cftr+/+ organoids, but this difference is not significant at p ≤ 
0.05 (p=0.4204). The expression data of both Scd1 and Aldha1a1 show that the LXR 
agonist influences the stem cell compartment (organoids) and differential expression of 
Cftr has an effect either on the expression of these genes in response to treatment with 
GW3965 in organoids. Only one biological replicate was evaluated in this experiment. 
More replicates are needed to confirm or refute this result. 
 
Figure 10. Expression of Aldh1a1 in Cftr+/+ and Cftr -/-  organoids treated with GW3965. 
The basal level of Aldh1a1 expression is slightly increased in Cftr  -/-  organoids compared 
to Cftr +/+ organoids. The expression of Aldh1a1 in response to LXR/RXR pathway 
agonist GW3965 is stronger in Cftr+/+ organoids than Cftr -/-  organoids. The standard 
error for technical replicates is shown by the error bars. 
 
 We also analyzed expression of claudin 4 (Cldn4), an integral membrane protein 
that is a component of tight junction strands (Figure 11). As expected, Cldn4 expression 
did not change due to treatment with LXR agonist GW3965, as it is not a target gene of 
the LXR/RXR pathway. Interestingly, the basal expression level of Cldn4 is higher in 
Cftr -/- organoids, but this difference is not significant at p ≤ 0.05 (p=0.7172).  
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Figure 11. Expression of Cldn4 in Cftr +/+ and Cftr -/-  organoids treated with GW3965. 
The basal level of Cldn4 expression is higher in Cftr -/-  organoids compared to Cftr +/+ 
organoids. The expression of Cldn4 in response to LXR/RXR pathway agonist GW3965 
does not change in Cftr +/+ organoids and Cftr -/-  organoids. The standard error for 
technical replicates is shown by the error bars. 
 
To confirm the differences in basal expression levels of Scd1 and Aldh1a1, we analyzed 
expression of these genes in Cftr +/+ and Cftr -/- organoids derived from three distinct and 
separate pairs of littermate mice (Figure 12). Similar to the expression levels of the 
previous analysis, Scd1 was expressed at a higher level in Cftr +/+ organoids compared to 
Cftr -/-  organoids, but this difference was not significant at p ≤ 0.05 (p=0.4577, Figure 
12a). Aldh1a1 was expressed at a higher level in Cftr -/- organoids compared to Cftr +/+ 
organoids, but again, this difference was not significant at p ≤ 0.05 (p=0.4478, Figure 
12b), which is consistent with the previous basal level expression data. This experiment 
was performed using only one biological replicate. More replicates must be obtained and 
evaluated to confirm or refute these results. 
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Figure 12. Expression of Scd1 and Aldh1a1 in Cftr +/+ and Cftr -/-  organoids. a. The level 
of Scd1 expression is increased in Cftr +/+ organoids compared to Cftr  -/-  organoids. b. 
The expression level of Aldh1a1 is increased in Cftr -/- organoids compared to Cftr +/+ 
organoids. 
 
 
Discussion 
 
 The purpose of this thesis was to determine the role of KCNQ1 and CFTR as 
colorectal cancer tumor suppressors by their regulation of the intestinal stem cell 
compartment. It was our goal to characterize the tumor suppressive mechanisms of these 
genes and their effect on the stem cell compartment by analyzing phenotypic differences 
and gene expression changes of organoids. Organoids are cultures of isolated intestinal 
stem cells that recapitulate the self-renewal and differentiation capacity of the tissue they 
are derived from. Thus, organoids provide a better physiological in vitro model than 
traditional monolayer culture techniques (Sato et al., 2011). Our data support our 
hypothesis that loss of KCNQ1 or CFTR influences changes to the intestinal stem cell 
compartment. Although our data does not provide a comprehensive mechanism by which 
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KCNQ1 or CFTR acts as a colorectal cancer tumor suppressor, the data does provide 
insight to possible biological pathways that may be involved.  
 
Kcnq1 is expressed at the base of the colonic crypt 
 Our working model is that Kcnq1 is a tumor suppressor by its effect on the 
regulation of the stem cell compartment. We analyzed the expression and localization of 
Kcnq1 in the colonic tissue of mice by immunohistochemical analysis. Kcnq1 is 
expressed at the base of the colonic crypt (Figure 1), with its expression diffusing until it 
is absent near the crypt-villus junction. The localization and expression of Kcnq1 
supports our hypothesis because it confirms that Kcnq1 is expressed where the stem cells 
reside. There are an estimated four to six stem cells per crypt that express the intestinal 
stem cell marker Lgr5 (Barker et al., 2007). These stem cells are located immediately 
above Paneth cells in the small intestine, which are also located at the crypt base (Barker 
et al., 2007). Because we confirmed that Kcnq1 is expressed at the base of the crypt, 
where the stem cells reside, it is possible that Kcnq1 exerts its tumor suppressive 
mechanism by influencing the stem cell compartment of the intestinal tissue, because it is 
spatially expressed in proximity to the stem cells. Our immunohistochemical analysis 
agrees with other previously published data by Preston et al., who also showed that 
Kcnq1 is expressed in the basolateral membrane of colonic crypt cells, and is not 
expressed near the top of the crypt (2011).  
Organoids deficient in Kcnq1 or Cftr have increased cell viability 
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 Previous data from our lab and collaborators defines KCNQ1 and CFTR as human 
colorectal cancer tumor suppressor genes. We hypothesized that loss of either Kcnq1 or 
Cftr in mice would affect the stem cell compartment of the intestinal tissue, and thus 
cause oncogenic phenotypes. To evaluate this, we harvested intestinal organoids from 
either Kcnq1 +/+ and Kcnq1 -/-  or Cftr +/+ and Cftr -/- littermate paired mice. Organoids 
were used in this assay and throughout this thesis work to evaluate the effects loss of 
Kcnq1 and Cftr had on the stem cell compartment specifically, since this is where 
colorectal cancer originates from. We analyzed the cell viability of these organoids using 
MTT, a colorimetric assay that measures the activity of cellular enzymes that convert the 
MTT dye to an insoluble blue form. Thus, the measured absorbency is representative of 
the number of viable cells in culture.  
 Kcnq1 +/+ and Kcnq1 -/-  organoids were plated at four relative dilutions for the 
MTT assay (100, 75, 50, and 25). To analyze the absorbency data, the percent MTT 
signal was calculated by considering the WT “100” dilution as a value of one, and 
comparing the other values to this. In all four dilutions of organoids, the Kcnq1 -/-  
organoids had a slightly higher percent MTT signal compared to the four respective 
dilutions of the Kcnq1 +/+ organoids (Figure 2a). This difference in MTT signal was less 
than 1.5-fold and was not statistically significant.  
 Cftr +/+ and Cftr -/- organoids were also analyzed by MTT assay. These results are 
like that of Kcnq1 organoids, in that the percent MTT signal is slightly higher (less than 
1.5-fold difference) in all four dilutions of Cftr -/- organoids when compared to Cftr +/+ 
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organoids (Figure 2b). Although this difference is not statistically significant, it is a more 
pronounced difference than what was shown in comparable Kcnq1 MTT data.  
 The results of this MTT analysis were not expected. We hypothesized that loss of 
Kcnq1 or Cftr would cause oncogenic changes to the stem cell compartment, such as an 
increase in cell viability. Similar studies by a previous member of our lab, Dr. Bich Than, 
analyzed development of colonic organoids derived from Kcnq1 +/+ and Kcnq1 -/-  or Cftr 
+/+ and Cftr -/- littermate paired mice (2014 and 2016, respectively). Colon organoids were 
harvested from a group of Kcnq1 +/+ and Kcnq1 -/-  age and gender matched mice and 
grown for five days, and organoid growth was monitored on days two through five. Than 
et al. found that loss of Kcnq1 increased the number of colon organoids by more than 
three-fold, a statistically significant difference (2014). Than et al. performed a similar 
analysis in 2016 with Cftr +/+ and Cftr -/-  mice, and measured a 2.3-fold growth difference 
in organoids derived from Cftr -/-  mice, a statistically significant result (2016). 
Considering this data, it was surprising that the MTT cell viability assay did not show 
greater differences between organoids derived from from Kcnq1 +/+ and Kcnq1 -/-  or Cftr 
+/+ and Cftr -/- littermate paired mice. There are a few fundamental differences in the 
assays that may account for this discrepancy. While the studies by Than et al. showed a 
statistically significant increase in development of organoids due to loss of Kcnq1 or Cftr, 
both analyses noted there were no obvious morphological differences between the KO 
and WT organoids. It is possible that the MTT assay is not sensitive enough to determine 
small differences in cell viability, and this may be reflected in our data. Another 
difference that may account for the discrepancy between the data is the organoids used in 
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Than et al.’s studies were derived from colonic tissue, while our organoids were derived 
from small intestinal tissue. Colorectal cancer arises from the colon, and while the small 
intestinal tissue physiology is comparable to the large intestine (colon), it is not the same. 
The difference in cell viability detected by MTT may more accurately reflect the 
differences in organoid development seen by Than et al. if the organoids used for the 
MTT assay were instead derived from colonic tissue. As these experiments were 
underway, we were also working to develop a protocol for the isolation and culturing of 
colonic organoids. This protocol is now established, and these experiments may be 
repeated in the future using colonic organoids. 
Kcnq1 -/- organoids exhibited a decreased unfolded protein response 
 Loss of Kcnq1 causes decreased activation of the unfolded protein response in 
intestinal organoids. Our initial analysis of organoid mRNA expression data obtained by 
Illumina Next-Generation RNA Sequencing utilized GSEA by the Broad Institute. GSEA 
allows the investigator to define biological or genetic phenotypes in a large expression 
dataset and compare the expression of predetermined gene sets to determine if a 
phenotype is enriched or depleted for those genes. We isolated mRNA from organoids 
derived from pairs of Kcnq1 +/+ and Kcnq1 -/-  age and gender matched mouse small 
intestine. This mRNA expression data was analyzed by GSEA, with the two phenotypes 
defined as Kcnq1 +/+ and Kcnq1 -/-. From this analysis it was determined that the unfolded 
protein response gene set is enriched in Kcnq1 +/+ organoids, and thus depleted in Kcnq1 -
/-  organoids (Figure 4). This data suggests loss of Kcnq1 expression affects either the 
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activation of the unfolded protein response in intestinal stem cell culture, or the response 
of the intestinal stem cells to activation of the UPR. 
 Although GSEA is informative, the conclusions that we draw from these analyses 
are limited. To further investigate the depleted expression of UPR genes in Kcnq1 -/- 
organoids, we proceeded with functional assays. Organoids derived from pairs of Kcnq1 
+/+ and Kcnq1 -/-  age and gender matched mice small intestine were treated with 
Thapsigargin, an inducer of the unfolded protein response. After treatment, RNA was 
isolated from treated and control organoids and analyzed by RT-qPCR. To determine if 
the unfolded protein response was activated in the stem cell compartment by 
Thapsigargin, we analyzed expression of UPR target genes Atf4 and Hspa5. The increase 
in expression of these target genes upon treatment with Thapsigargin in both the WT and 
KO organoids (greater than 1.5-fold difference) indicated the treatment was inducing the 
UPR in organoids, as expected. Atf4 is an activating regulatory element that is part of the 
unfolded protein response. Atf4 causes transcriptional changes resulting in increases in 
protein folding, transport, and ER-associated protein degradation, while attenuating 
protein synthesis (Wang and Kaufman, 2014). There is no notable difference between the 
basal expression levels of Atf4 in Kcnq1 +/+ and Kcnq1 -/-  organoids (Figure 5). However, 
after treatment with Thapsigargin and induction of the unfolded protein response, the 
expression of Atf4 increases (more than 1.5-fold) in both Kcnq1 +/+ and Kcnq1 -/-  
organoids. Comparison of the response of Kcnq1 +/+ and Kcnq1 -/-  organoids to induction 
of the UPR reveals that Kcnq1 -/-  organoids illicit a weaker response than Kcnq1 +/+ 
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organoids, as the expression level of Atf4 in Thapsigargin treated Kcnq1 -/-  organoids is 
less than that of Kcnq1 +/+ organoids.  
 Expression of Hspa5 in Kcnq1 +/+ and Kcnq1 -/-  organoids showed a similar trend. 
Hspa5 encodes the endoplasmic reticulum luminal glucose-regulated protein 78 (Grp78), 
which is an integral component of the unfolded protein response. Grp78 is a signaling 
regulator that binds to and maintains ER stress sensors PERK, ATF6, and IRE1. Upon 
ER stress, Grp78 is titrated away through binding to misfolded proteins, with allows the 
dimerization of PERK and IRE1 and triggers activation of their downstream signaling 
pathways (Lee, 2014). The basal expression levels of Hspa5 is similarly low in both 
Kcnq1 +/+ and Kcnq1 -/-  organoids (Figure 6). After treatment with Thapsigargin and 
induction of the unfolded protein response, the expression of Hspa5 increases (more than 
1.5-fold) in both Kcnq1 +/+ and Kcnq1 -/-  organoids. Comparison of the response of Kcnq1 
+/+ and Kcnq1 -/-  organoids to induction of the UPR reveals that Kcnq1 -/-  organoids illicit 
a weaker response than Kcnq1 +/+ organoids, as the expression level of Hspa5 in 
Thapsigargin treated Kcnq1 -/-  organoids is less than that of Kcnq1 +/+ organoids. The 
difference between these two responses is less than 1.5-fold. It should be noted that the 
expression signal is very low. This may be due to the UPR being mostly restricted to the 
stem cell compartment, which represents only a fraction of the cells in an organoid. 
 These data suggest loss of Kcnq1 influences the unfolded protein response in the 
intestinal stem cell compartment. The expression of UPR target genes Atf4 and Hspa5 in 
response to induction of the UPR by Thapsigargin was lower in Kcnq1 -/-  organoids 
compared to Kcnq1 +/+ organoids. Thus, loss of Kcnq1 has an effect either on the 
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expression of these target genes in response to induction of the UPR, or on the response 
of organoids to the treatment with Thapsigargin.  
 Contrary to our data, previously established models of endoplasmic reticulum 
stress responses in cancer assert that many types of cancer cells increase expression of 
ER stress-related genes and proteins (Moenner et al., 2007). The theory states that 
pathologic states (such as cancer) involve deregulation of ER homeostasis, and thus the 
ability of cells to handle these stresses conditions their intrinsic capacity to adapt for cell 
survival or enter apoptosis or senescence through ER-associated pathways (Xu et al., 
2005). Recent studies have demonstrated roles for UPR signaling in tumor growth and 
chemoresistance and that in vivo UPR activation is a crucial step during oncogenic 
transformation and cancer development (Wang and Kaufman, 2014). Interestingly, 
previous studies show Grp78 expression is increased in colon cancers (Moenner et 
al.,2007) and activation of BIP is correlated with high cell malignancy (Wang and 
Kaufman, 2014). Studies by Wang et al. (2012) and Madhevan et al. (2011) showed that 
during malignant progression, cancer cells activate pathways, such as the immune 
response, that may require UPR signaling to meet cellular needs by increasing folding 
and secretion of cytokines, angiogenesis factors, and extracellular matrix components. In 
addition to these intrinsic factors, rapidly dividing cancer cells are frequently required to 
thrive in hostile environments, which could also cause activation of the UPR by 
disruption of ER protein folding (Wang and Kaufman, 2014). Collectively, these data 
suggest a role, and possibly a requirement, of UPR activation in cancer cells. 
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 Although the established model is that cancer cells exhibit increased UPR 
activation due to intrinsic and extrinsic stressors, our data show that loss of the tumor 
suppressor gene Kcnq1 in intestinal organoids causes decreased expression of UPR target 
genes compared to wildtype organoids. The difference in these results could be due to 
general considerations that must be noted when studying the UPR in cancer. For 
example, the deletion of a gene may be activating in terms of the UPR for the first 24 
hours, but detrimental for survival of the cell long-term. Thus, detailed kinetic studies 
analyzing multiple time points after gene knockdown are necessary to determine the full 
effect of loss of expression of a gene on the UPR. Another consideration to note is the 
induction of the UPR via pharmacological agents, such as Thapsigargin. This agent may 
have multiple effects on the cell, and thus physiologic challenges (such as hypoxia, 
nutrient deprivation, and reactive oxygen species) better model the environment of the 
cancer cell and can lead to different effects on the UPR.  
 Previous studies have demonstrated that UPR activation enhances the protein 
folding capacity of cancer cells to meet the demand for cell survival and protects cancer 
cells from stress-induced cell death (Wang and Kaufman, 2014). However, recent data 
have challenged this model, and may provide a better comparison for our own studies.  
Heijmans et al. found that UPR activation is involved in cell fate decisions and 
demonstrated that ER stress and UPR activation is low in intestinal stem cells (2013). 
This study also showed that activation of Perk-elF2α signaling alone is capable of 
inducing intestinal epithelial stem cell differentiation. These data suggest that the UPR 
may regulate intestinal epithelial stem cell differentiation. To further investigate how the 
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UPR regulates intestinal epithelial cell differentiation in a model that more closely 
resembles cancer, van Lidth de Jeude et al. analyzed cells that had acquired oncogenic 
mutations. van Lidth de Jeude found that loss of Apc alone, a common mutation in CRC, 
resulted in crypt elongation, activation of the Wnt signature, and accumulation of 
intestinal stem cells. This oncogenic phenotype was completely rescued upon activation 
of ER stress by additional deletion of Grp78 (2016). In Grp78 Apc double knockout 
mice, stem cells were lost and repopulation of the stem cell population occurred by non-
mutant cells only, which implies these double-knockout mice had lost the capacity to 
self-regenerate (2016). These data suggest a role for UPR activation in inducing stem 
cells to differentiate. Along this line, a decreased response to UPR activation could lead 
to maintenance of the stem cell phenotype in CRC. Heijmans et al. data supports this. 
They found that Thapsigargin-induced UPR activation caused repression of intestinal 
stem cell markers Lgr5 and Ascl2.  
 To investigate this further, we analyzed the expression of Lgr5 and Ascl2 in 
organoids derived from one pair of Kcnq1 +/+ and Kcnq1 -/-  age and gender matched mice 
treated with Thapsigargin, and inducer of the unfolded protein response. Although the 
basal level of both of these stem cell markers was higher in Kcnq1 -/-  organoids, upon 
treatment with Thapsigargin, the expression of these markers drastically decreased (more 
than 1.5-fold) and in the Kcnq1 -/-  organoids, the expression of Ascl2 and Lgr5 was 
lower. This result suggests that upon ER stress, loss of Kcnq1 has some effect on the stem 
cell compartment’s differentiation and loss of stem-cell markers.  
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 Our previous data show Kncq1 is a tumor suppressor gene in CRC, and biological 
pathway analysis by gene expression data revealed loss of Kcnq1 may be involved in the 
unfolded protein response. The experiments in this thesis confirm that loss of Kcnq1 
causes a decreased activation of the UPR upon induction of ER stress in the intestinal 
stem cell compartment. While these UPR experiments provide interesting data, it must be 
further explored and better understood. The UPR is an attractive target for drug discovery 
because of its inducible nature and demonstrated plasticity. However, it is apparent that 
loss of individual genes has unique effects on the UPR, and thus it is difficult to 
characterize how an entire tissue or organ will respond to UPR activation or suppression. 
It is also crucial to fully characterize the influence of the UPR on cancer cells, and if this 
influence is different at different stages of cancer development and progression. The 
exploratory work in this thesis provides a framework by which future studies can be 
focused on.  
Cftr -/- organoids exhibited decreased LXR/RXR pathway activation 
 Loss of Cftr expression causes decreased activation of the LXR/RXR pathway in 
intestinal organoids. Previous work from our lab analyzed Cftr normal and deficient 
colon, small intestine, and tumors to determine what biological pathways were affected 
by loss of Cftr (Than et al., 2016). IPA revealed Cftr-deficient normal and tumor tissue 
had a decreased activation of the LXR/RXR pathway. To further investigate the depleted 
activation of the LXR/RXR UPR pathway due to loss of Cftr, we proceeded with 
functional assays. Organoids derived from one pair of Cftr +/+ and Cftr -/-  age and gender 
matched mouse small intestine were treated with GW3965, an activator of the LXR/RXR 
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pathway. After treatment, RNA was isolated from treated and control organoids and 
analyzed by RT-qPCR. To determine if the LXR/RXR pathway was activated in the stem 
cell compartment by GW3965, we analyzed expression of LXR target genes Scd1 and 
Aldh1a1. The increase in expression of these target genes upon treatment with GW3965 
in both the WT and KO organoids (greater than 1.5-fold difference) indicated the 
treatment was activating the LXR/RXR pathway in organoids, as expected. We then 
proceeded to analyze target gene expression levels. Scd1 encodes an enzyme that 
produces monounsaturated fatty acids, which are an important molecule for a multitude 
of biological processes. Its relation to cholesterol biosynthesis processes makes it a target 
of the LXR/RXR pathway. The basal expression level of Scd1 was low and unchanged 
due to loss of Cftr in organoids (Figure 9). After treatment with GW3965, the expression 
of Scd1 increased (more than 1.5-fold) in both Cftr +/+ and Cftr -/-  organoids. The 
expression of Scd1 in response to treatment with GW3965 is significantly lower in Cftr -/-  
organoids compared to Cftr +/+ organoids (more than 1.5-fold). This confirms the results 
of the IPA analysis of Cftr deficient tissue, which showed that loss of Cftr caused 
decreased activation of the LXR/RXR pathway.  
 Another target gene of the LXR/RXR pathway is Aldh1a1, a major enzyme in the 
oxidative pathway of alcohol metabolism. The basal expression levels of Aldh1a1 were 
relatively unchanged due to loss of Cftr in organoids (Figure 10). In response to treatment 
with GW3965, the expression of Aldh1a1 is significantly lower in Cftr -/-  organoids 
compared to Cftr +/+ organoids (more than 1.5-fold). This agrees with the Scd1 expression 
data as well as the previously published IPA analysis (Than et al., 2016), which showed 
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that loss of Cftr affects the response of the intestinal stem cell compartment to activation 
of the LXR/RXR pathway.  
 The LXR/RXR pathway was of initial interest to our lab as a potential biological 
pathway affected by the loss of Cftr not only because of its consistency as a finding in 
numerous expression analyses, but also because of its well-established involvement in 
cancer. Accelerated cholesterol and lipid metabolism are hallmarks of cancer, as 
proliferating cells increase cholesterol uptake due to the requirement for cholesterol in 
eukaryotic membranes (Gabitova et al., 2014). Liver X receptors (LXR) are regulators of 
the cholesterol homeostasis network and coordinate growth with the availability of 
cholesterol (Gabitova et al., 2014). Activation of the LXR/RXR pathway increases 
cholesterol efflux through ATP-binding cassette (ABC) class A transporters and thus 
decreases the amount of intracellular cholesterol (Gabitova et al., 2014). Our data support 
a model whereby loss of the tumor suppressor gene Cftr in intestinal organoids causes 
decreased activation of the LXR/RXR pathway and leads to increased intracellular 
cholesterol. Increased cholesterol requirements is characteristic of rapidly proliferating 
and cancer cells.  
 The experiments in this thesis support the previously published IPA data that Cftr- 
deficient tissues exhibit inhibition of the LXR/RXR pathway. This conclusion may 
explain the functional mechanism of tumor suppression by Cftr in mouse intestinal stem 
cell compartments. Loss of Cftr expression either affects the activation of the LXR/RXR 
pathway in organoids or affects the response of the organoids to activation of the 
LXR/RXR pathway. It is important to understand if this inhibition causes increased 
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intracellular cholesterol levels overall, or if the tumor suppressive mechanism is not 
directly related to cholesterol levels in the cell. This model is important to pursue and 
characterize because nuclear receptors, such as LXR, are an important class of drug 
targets as their ligands easily pass biological membranes due to their lipophilic nature. If 
loss of Cftr causes oncogenic changes to the stem cell compartment through increase of 
intracellular cholesterol levels, it may be a promising target for drug development. 
 
GSEA of human tumors determined loss of KCNQ1 or CFTR is related to enrichment of 
inflammatory pathway genes 
 To better understand which biological pathways were affected by loss of KCNQ1 
and CFTR in human colorectal cancers, we used GSEA to analyze biological gene sets 
that were enriched or depleted in the KCNQ1 or CFTR low phenotype. Three sets of 
human colorectal primary tumor mRNA expression data were sorted continuously, from 
KCNQ1 or CFTR low to high expression. GSEA (Broad Institute) was run on these 
expression datasets using the GEO Molecular signatures gene set “hallmarks of cancer.” 
The top four gene sets that were determined as enriched in the KCNQ1 low phenotype in 
all three colorectal tumor mRNA expression datasets are shown in Table 1. The KCNQ1 
low tumor phenotype was enriched in the following gene sets; epithelial mesenchymal 
transition, inflammatory response, allograft rejection, and interferon gamma response. 
The top four gene sets that were determined as enriched in the CFTR low phenotype in all 
three colorectal tumor mRNA expression datasets are shown in Table 3. The CFTR low 
tumor phenotype was enriched in the following gene sets; epithelial mesenchymal 
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transition, inflammatory response, TNF signaling via NF-κB, and angiogenesis. These 
gene sets represent biologically relevant groups of genes that share involvement in a 
specific biological pathway. Thus, it can be inferred that these pathways are enriched in 
the KCNQ1 or CFTR low phenotype. 
 A majority of the gene sets enriched in the KCNQ1 and CFTR low phenotypes are 
involved in the inflammatory response. Inflammation has long since been established as a 
colorectal cancer phenotype, and many studies suggest inflammatory mechanisms play a 
causal role in cancer development and progression. A study by McMillan, Canna, and 
McArdle in 2003 examined the relationship of the systemic inflammatory response and 
disease-free survival of CRC patients. They studied a total of 174 patients considered to 
have undergone curative resection and measured inflammatory response in these patients 
by recording circulating concentrations of C-reactive protein (CRP), a protein made by 
the liver and released into the blood upon inflammation (McMillan et al., 2003). The 
study found that the presence of a systemic inflammatory response predicts a poor 
outcome in colorectal cancer patients who have undergone potentially curative resection 
surgery (McMillan et al., 2003). More recent and detailed molecular studies show that 
many inflammation-associated genes, such as cyclooxygenase-2, nitric oxide synthase-2, 
and the interferon-inducible gene 1-8U are elevated in colonic neoplasms (Itzkowitz and 
Yio, 2004). Multiple knockout studies show that when inflammatory genes are disrupted, 
mice develop oncogenic phenotypes. For example, transgenic mice with disruption of IL-
10 develop adenocarcinomas after three and six months in 25 and 60% of the mice, 
respectively (Shattuck-Brandt et al., 2000). A leading theory of how inflammation plays 
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a causal role in CRC development and progression is that the oxidative stress caused by 
chronic inflammation contributes to neoplastic transformation and a cancer-prone 
phenotype (Hussain et al., 2003). Despite much effort, the mechanism of how 
inflammation causes CRC is not fully understood. The finding that inflammatory gene 
sets are enriched in both KCNQ1 and CFTR low expressing human CRC tumors is a 
potential insight into the mechanism of tumor suppression by these two genes.  
 Another gene set significantly enriched in both KCNQ1 and CFTR low expressing 
human tumor phenotypes was the epithelial-mesenchymal transition, a biologic process 
that allows a polarized epithelial cell in contact with the basement membrane to undergo 
multiple changes that enable it to transition to a mesenchymal cell phenotype (Kalluri and 
Weinberg, 2009). This cellular process is yet another well-researched area in which data 
supports its involvement in cancer. Epithelial-mesenchymal transitions represent an 
important source of mesenchymal cells that participate in pathological processes, such as 
tumor invasiveness and metastasis (Kalluri and Weinberg, 2009). Mesenchymal cells 
exhibit increased production of extracellular matrix components, increased resistance to 
apoptosis, and enhanced migratory capacity and invasiveness (Kalluri and Weinberg, 
2009). Studies of immortalized human mammary epithelial cells by Mani et al. in 2008 
showed that the induction of the epithelial-mesenchymal transition not only resulted in 
the acquisition of mesenchymal traits, but also the expression of stem-cell markers as 
well as the increased ability to form mammospheres and tumors more efficiently (Cell, 
2008). Although comparable work has not been extensively performed for intestinal 
tissue, the GSEA results that low expression of both KCNQ1 and CFTR in human tumor 
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tissue is associated with increased gene expression of epithelial-mesenchymal transition 
genes provides a possible mechanism for tumor suppression by these genes, and should 
be further explored.  
GSEA of Kcnq1 - / - Organoids Revealed Similar Enrichment as Human Colon Tumors 
 We used GSEA (Broad Institute) to analyze changes in gene expression related to 
biological pathways in Kcnq1 +/+ and Kcnq1 -/-  organoids. We were interested to compare 
the GSEA analysis for Kcnq1 -/-  organoids compared to the GSEA analysis of human 
tumor tissue with low expression of KCNQ1. The enriched gene sets and their statistical 
values are reported in Table 2. The epithelial-mesenchymal transition gene set was 
enriched in the Kcnq1 -/-  organoids, similar to the enrichment of this gene set in both the 
KCNQ1 and CFTR low-expression human tumor phenotype. Another common pathway 
enriched in both the Kcnq1 -/-  organoids and the KCNQ1 low-expression human tumor 
tissues is the inflammatory response. Although the IL-6 JAK-STAT3 signaling pathway 
was found to be enriched in Kcnq1 -/-  organoids but not in the human tissue analysis, this 
gene set is involved in inflammation, which is consistent with the other gene sets 
upregulated in the analysis of human tissues. These similarities are interesting because 
they provide a qualitative analysis of the similarity between the two models: organoids 
derived from mice and human colon tumor tissue samples. The commonalities in 
enriched gene sets determined by GSEA allows us to confirm that our biological 
pathways of interest are of relevance in human tissues as well.  
 The cholesterol homeostasis gene set was enriched in the Kcnq1 -/-  organoids we 
analyzed. This finding is consistent with the well-established oncogenic phenotype found 
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in many types of cancers, due to the increased demand for cholesterol in rapidly 
proliferative cells. A dysregulation of cholesterol homeostasis was also found in 
previously published IPA analysis of CFTR-deficient tissues (Than et al., 2016). Because 
KCNQ1 and CFTR have interrelated functions in the intestinal epithelium, it is interesting 
but not surprising that knockout of one of these genes has interrelated and similar effects 
as the other.  
Conclusions and Future Directions 
 Our preliminary data support a role for KCNQ1 and CFTR as colorectal cancer 
tumor suppressor genes. The experiments in this thesis support our hypothesis that loss of 
KCNQ1 or CFTR is related to changes of the intestinal stem cell compartment phenotype, 
or of organoids. Specifically, our data show that loss of CFTR expression has an effect on 
the LXR/RXR pathway response in organoids, and that loss of KCNQ1 expression has an 
effect on the unfolded protein response in organoids. GSEA of human CRC tumor 
mRNA expression data revealed that both loss of KCNQ1 and CFTR expression in these 
tissues affects many pathways, including the immune response and epithelial-
mesenchymal transition. These responses may be implicated in the tumor suppressive 
function of KCNQ1 and CFTR.  
 Further work must be completed to characterize the functional mechanism of 
tumor suppression by KCNQ1 and CFTR. Firstly, the expression of Cftr must be 
characterized in the mouse colon. It is known that the protein is expressed in the intestinal 
epithelium, but it has yet to be determined if the protein is expressed in the base of the 
crypt, where the stem cells reside. This expression data would confirm our working 
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model of tumor suppression by Cftr, that the protein exerts its tumor suppressive effects 
on the intestinal stem cell compartment.  
 The phenotypic differences between Kcnq1 and Cftr wildtype and knockout 
organoids must be further characterized. Although the MTT assay detected small 
differences between cell viability of the organoids, observational data suggests there are 
physical differences in the integrity of the organoids. Numerous times during the 
harvesting and plating procedure of intestinal organoids, we noticed the organoids 
derived from knockout tissue were more fragile and easily disrupted. Often, organoids 
derived from knockout tissues did not grow well in culture after being disrupted during 
the harvesting process. These observations suggest some sort of cell adhesion or cell 
integrity difference between wildtype and knockout tissues. This phenotype would be 
important to characterize because it may play a role in the metastasis and progression of 
CRC. To analyze these differences, immunohistochemical analysis of proteins known to 
have functional roles in cell adhesion and movement would be informative. Functional 
assays that involved mechanical disturbance of organoids and then colony forming 
analysis would also be useful. In general, understanding and fully characterizing the 
phenotypic differences between organoids derived from wildtype and knockout tissue 
(Kcnq1 and Cftr) is a crucial step to understanding the tumor suppressive mechanisms of 
these genes.  
 Organoids were used in this thesis because they provide a physiologically relevant 
in vitro model. However, we discovered that replicating experiments with organoids was 
difficult, because they are such a direct representation of the tissue they are derived from, 
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and naturally, tissue characteristics vary from animal to animal. These differences must 
be reconciled and standardized by making cell stock lines to make organoids a more 
useful experimental model. Considering this, more functional assays are needed to further 
characterize the responses of organoids to agonists of specific pathways we are interested 
in, for example, the LXR/RXR pathway and the unfolded protein response. In addition, it 
would be informative to investigate the response of organoids to activation of the other 
pathways found in our GSEA, such as inflammation. There are many interesting assays 
possible that involve the immune response, but what would be most informative at this 
point is to fully characterize the changes in the immune response of organoids that do not 
express Kcnq1 or Cftr.  
 Our data support the role of KCNQ1 and CFTR as tumor suppressors in human 
colorectal cancers. Understanding the mechanism of tumor suppression could help 
develop more effective therapy for CRC. Gaining knowledge about the mechanism will 
also help identify at-risk individuals, and identify which individuals require more 
aggressive treatment and disease surveillance. 
 
 
 
 
 
 
 
  77 
References 
 
1. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., and Vogelstein, B. 
(1990). Suppression of human colorectal carcinoma cell growth by wild-type p53. 
Science, 249, 912. 
2. Barker, N. et al. (2007). Identification of stem cells in small intestine and colon 
by marker gene Lgr5. Nature 449, 1003-1007. 
3. Barker, N. et al. (2008). The intestinal stem cell. Genes Dev. 22, 1856-1864. 
4. Blackiston, D.J. et al. (2009).  Bioelectric controls of cell proliferation: Ion 
channels, membrane voltage, and the cell cycle. Cell Cycle 21, 3519-3528. 
5. Bos, J.L. et al. (1987). Prevalence of RAS gene mutations in human colorectal 
cancers. Nature 327, 293-297.  
6. Bovenga, F., Sabbà, C., and Moschetta, A. (2015). Uncoupling nuclear receptor 
LXR and cholesterol metabolism in cancer. Cell Metabolism 21, 517-526. 
7. Cao, S. S., and Kaufman, R. J. (2012). Unfolded protein response. Current 
Biology 22, 622-626. 
8. Casimiro, M. C., Knollmann, B. C., Ebert, S. N., Vary, J. C., Greene, A. E., 
Franz, M. R., and Pfeifer, K. (2001). Targeted disruption of the Kcnq1 gene 
produces a mouse model of Jervell and Lange–Nielsen Syndrome. Proceedings of 
the National Academy of Sciences 98, 2526-2531. 
9. Cho, K. R., and Vogelstein, B. (1992). Genetic alterations in the adenoma–
carcinoma sequence. Cancer 70, 1727-1731. 
10. Clevers, H. (2006). Wnt/β-catenin signaling in development and disease. Cell 
127, 469-480. 
11. Dedek K, and Waldegger S. (2001). Colocalization of KCNQ1/KCNE channel 
subunits in the mouse gastrointestinal tract. Eur. J. Physiol. 442, 896-902. 
12. de Jeude, J.V.L., Meijer, B.J., Wielenga, M.C.B., Spaan, C.N., Baan, B., 
Rosekrans, S.L., and Paton, A.W. (2016). Induction of endoplasmic reticulum 
stress by deletion of Grp78 depletes Apc mutant intestinal epithelial stem cells. 
Oncogene 36, 3397-3405.  
13. De Lisle, R. C., and Borowitz, D. (2013). The cystic fibrosis intestine. CSH 
Perspectives in Medicine 3, a009753.  
14. Demolombe S, Franco D et al. (2001). Differential expression of KvLQT1 and its 
regulator IsK in mouse epithelia. Am J Physiol Cell Physiol. 280, 359-372.  
15. den Uil, S. H., Coupé, V. M., Linnekamp, J. F., van den Broek, E., Goos, J. A., 
Delis-van Diemen, P. M., and Medema, J. P. (2016). Loss of KCNQ1 expression 
in stage II and stage III colon cancer is a strong prognostic factor for disease 
recurrence. British Journal of Cancer 115, 1565–1574. 
16. Diener, M. Hug, F., Strabel, D. and Scharrer, E. Cyclic AMP-dependent 
regulation of K+ transport in the rat distal colon. British Journal of Pharmacology, 
118, 1477-1487. 
17. Farin, H. F., Jordens, I., Mosa, M. H., Basak, O., Korving, J., Tauriello, D. V., 
and Clevers, H. (2016). Visualization of a short-range Wnt gradient in the 
intestinal stem-cell niche. Nature 530, 340-343. 
  78 
18. Fodde, R., Kuipers, J., Rosenberg, C., Smits, R., Kielman, M., Gaspar, C., and 
Clevers, H. (2001). Mutations in the APC tumour suppressor gene cause 
chromosomal instability. Nature Cell Biology 3, 433-438. 
19. Gorin, A., Gabitova, L., and Astsaturov, I. (2012). Regulation of cholesterol 
biosynthesis and cancer signaling. Current Opinion in Pharmacology 12, 710-716. 
20. Harding, H. P., Novoa, I., Zhang, Y., Zeng, H., Wek, R., Schapira, M., and Ron, 
D. (2000). Regulated translation initiation controls stress-induced gene expression 
in mammalian cells. Molecular Cell 6, 1099-1108. 
21. Jameson, J., & Loscalzo, J. Harrison's Principles of Internal Medicine, 19e. 
22. Han, D., Lerner, A. G., Walle, L. V., Upton, J. P., Xu, W., Hagen, A., and Papa, 
F. R. (2009). IRE1α kinase activation modes control alternate endoribonuclease 
outputs to determine divergent cell fates. Cell 138, 562-575. 
23. Haze, K., Yoshida, H., Yanagi, H., Yura, T., and Mori, K. (1999). Mammalian 
transcription factor ATF6 is synthesized as a transmembrane protein and activated 
by proteolysis in response to endoplasmic reticulum stress. Molecular Biology of 
the Cell, 10, 3787-3799.  
24. Hodges, C. A., Cotton, C. U., Palmert, M. R., and Drumm, M. L. (2008). 
Generation of a conditional null allele for Cftr in mice. Genetics 46, 546-552. 
25. He, X.C. et al. (2004). BMP signaling inhibits intestinal stem cell self-renewal 
through suppression of Wnt–bold beta-catenin signaling. Nature Genetics 36, 
1117-1121. 
26. Hussain, S. P., Hofseth, L. J., and Harris, C. C. (2003). Radical causes of cancer. 
Nature Reviews Cancer, 3, 276-285. 
27. Itzkowitz, S. H., and Yio, X. (2004). Inflammation and cancer IV. Colorectal 
cancer in inflammatory bowel disease: the role of inflammation. Am. J. of Phys. 
Gastrointestinal and Liver Phys. 287, 7-17. 
28. Jespersen, T., Grunnet, M., and Olesen, S. P. (2005). The KCNQ1 potassium 
channel: from gene to physiological function. Physiology 20, 408-416. 
29. Kalluri, R. and Weinberg, R. A. (2009). The basics of epithelial-mesenchymal 
transition. The Journal of Clinical Investigation 119, 1420. 
30. Kaser, A., Flak, M. B., Tomczak, M. F., and Blumberg, R. S. (2011). The 
unfolded protein response and its role in intestinal homeostasis and inflammation. 
Experimental Cell Research 317, 2772-2779. 
31. Kaser, A. and Blumberg, R. S. (2010). Endoplasmic reticulum stress and 
intestinal inflammation. Mucosal Immunology 3, 11-16. 
32. Kasper, D.L. et al. (2012). Harrison’s Principles of Internal Medicine (19e.). 
McGraw Hill.  
33. Kinzler, K. W. and Vogelstein, B. (1996). Lessons from hereditary colorectal 
cancer. Cell 87, 159-170. 
34. Kunzelmann, K. (2005). Ion channels and cancer. The Journal of Membrane 
Biology 205, 159. 
35. Lee, A. S. (2014). Glucose-regulated proteins in cancer: molecular mechanisms 
and therapeutic potential. Nature Reviews Cancer 14, 263-276. 
  79 
36. Lin, C. Y. and Gustafsson, J. Å. (2015). Targeting liver X receptors in cancer 
therapeutics. Nature Reviews Cancer 15, 216-224. 
37. Mahadevan, N. R., Rodvold, J., Sepulveda, H., Rossi, S., Drew, A. F., and 
Zanetti, M. (2011). Transmission of endoplasmic reticulum stress and pro-
inflammation from tumor cells to myeloid cells. Proceedings of the National 
Academy of Sciences 108, 6561-6566. 
38. Maisonneuve, P., Marshall, B. C., Knapp, E. A., and Lowenfels, A. B. (2012). 
Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. 
Journal of the National Cancer Institute 105, 122-129. 
39. Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., ...and 
Campbell, L. L. (2008). The epithelial-mesenchymal transition generates cells 
with properties of stem cells. Cell 133, 704-715. 
40. McMillan, D. C., Canna, K., and McArdle, C. S. (2003). Systemic inflammatory 
response predicts survival following curative resection of colorectal cancer. 
British Journal of Surgery 90, 215-219. 
41. Moenner, M., Pluquet, O., Bouchecareilh, M., and Chevet, E. (2007). Integrated 
endoplasmic reticulum stress responses in cancer. Cancer Research 67, 10631-
10634. 
42. Morokuma, J., Blackiston, D., Adams, D. S., Seebohm, G., Trimmer, B., and 
Levin, M. (2008). Modulation of potassium channel function confers a 
hyperproliferative invasive phenotype on embryonic stem cells. Proceedings of 
the National Academy of Sciences 105, 16608-16613. 
43. Ni, M., and Lee, A. S. (2007). ER chaperones in mammalian development and 
human diseases. FEBS letters 581, 3641-3651. 
44. Preston, P., Wartosch, L., Günzel, D., Fromm, M., Kongsuphol, P., Ousingsawat, 
J., ... and Jentsch, T. J. (2010). Disruption of the K+ channel β-subunit KCNE3 
reveals an important role in intestinal and tracheal Cl− transport. Journal of 
Biological Chemistry 285, 7165-7175. 
45. Reya, T. and Clevers, H. (2005). Wnt signalling in stem cells and cancer. Nature 
434, 843-850. 
46. Riss, T. L., Moravec, R. A., Niles, A. L., Duellman, S., Benink, H. A., Worzella, 
T. J., and Minor, L. (2016). Cell viability assays. 
47. Saif, M. W., and Chu, E. (2010). Biology of colorectal cancer. The Cancer 
Journal 16(3), 196-201. 
48. Sansom, O. J., Reed, K. R., Hayes, A. J., Ireland, H., Brinkmann, H., Newton, I. 
P., ... and Clarke, A. R. (2004). Loss of Apc in vivo immediately perturbs Wnt 
signaling, differentiation, and migration. Genes & Development 18, 1385-1390. 
49. Sasso, G. L., Bovenga, F., Murzilli, S., Salvatore, L., Di Tullio, G., Martelli, N., 
... and Palasciano, G. (2013). Liver X receptors inhibit proliferation of human 
colorectal cancer cells and growth of intestinal tumors in mice. Gastroenterology, 
144(7), 1497-1507. 
50. Sato, T. and Clevers, H. (2013) Growing self-organizing mini guts from a single 
intestinal stem cell: mechanism and applications. Science 340, 1190-1194. 
  80 
51. Sato, T. et al. (2009). Single Lgr5 stem cells build crypt-villus structures in vitro 
without a mesenchymal niche. Nature 459, 262-265.  
52. Shattuck-Brandt, R. L., Varilek, G. W., Radhika, A., Yang, F., Washington, M. 
K., and DuBois, R. N. (2000). Cyclooxygenase 2 expression is increased in the 
stroma of colon carcinomas from IL–10−/− mice. Gastroenterology 118, 337-345. 
53. Sikandar, S.S. et al. (2010). NOTCH Signaling Is Required for Formation and 
Self-Renewal of Tumor-Initiating Cells and for Repression of Secretory Cell 
Differentiation in Colon Cancer. Cancer Research 70, 1469-1478. 
54. Starr, T.K. et al. (2009) A Transposon-based genetic screen in mice identifies 
genes altered in colorectal cancer. Science 323, 1747-1750. 
55. Starr, T.K. et al. (2011) A Sleeping Beauty transposon-mediated screen identifies 
murine susceptibility genes for adenomatous polyposis coli (Apc)-dependent 
intestinal tumorigenesis. PNAS 108, 5765-5770. 
56. Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., 
Gillette, M. A., ... and Mesirov, J. P. (2005). Gene set enrichment analysis: a 
knowledge-based approach for interpreting genome-wide expression profiles. 
Proceedings of the National Academy of Sciences, 102, 15545-15550. 
57. Than, BLN et al. (2013). The role of KCNQ1 in mouse and human 
gastrointestinal cancers. Oncogene 33, 3861-3868. 
58. Than, B. L. N., Linnekamp, J. F., Starr, T. K., Largaespada, D. A., Rod, A., 
Zhang, Y., ... and Niemczyk, A. (2016). CFTR is a tumor suppressor gene in 
murine and human intestinal cancer. Oncogene 35, 4179-4187. 
59. Todd, D. J., Lee, A. H., and Glimcher, L. H. (2008). The endoplasmic reticulum 
stress response in immunity and autoimmunity. Nature Reviews Immunology 8, 
663-674. 
60. Uno, S., Endo, K., Jeong, Y., Kawana, K., Miyachi, H., Hashimoto, Y., and 
Makishima, M. (2009). Suppression of β-catenin signaling by liver X receptor 
ligands. Biochemical Pharmacology 77, 186-195. 
61. Vallon, V., Grahammer, F., Volkl, H., Sandu, C. D., Richter, K., Rexhepaj, R., ... 
and Lang, F. (2005). KCNQ1-dependent transport in renal and gastrointestinal 
epithelia. Proceedings of the National Academy of Sciences of the United States 
of America 102, 17864-17869. 
62. van der Flier, L.G. and Clevers, H. (2009) Stem cells, self-renewal, and 
differentiation in the intestinal epithelium. Annu. Rev. Physiol. 71, 241-260.  
63. Vedin, L. L., Gustafsson, J. Å., and Steffensen, K. R. (2013). The oxysterol 
receptors LXRα and LXRβ suppress proliferation in the colon. Molecular 
Carcinogenesis 52, 835-844. 
64. Wang, M. and Kaufman, R. J. (2016). Protein misfolding in the endoplasmic 
reticulum as a conduit to human disease. Nature 529, 326-335. 
65. Wang, S. and Kaufman, R. J. (2012). The impact of the unfolded protein response 
on human disease. J Cell Biol. 197, 857-867. 
66. Warth, R., Alzamora, M. G., Kim, J., Zdebik, A., Nitschke, R., Bleich, M., ... and 
Kim, S. (2002). The role of KCNQ1/KCNE1 K+ channels in intestine and 
  81 
pancreas: lessons from the KCNE1 knockout mouse. Pflugers Archiv. European 
Journal of Physiology 443, 822-828. 
67. Xu, C., Bailly-Maitre, B., and Reed, J. C. (2005). Endoplasmic reticulum stress: 
cell life and death decisions. Journal of Clinical Investigation 115, 2656. 
68. Yasuda, K., Miyake, K., Horikawa, Y., Hara, K., Osawa, H., Furuta, H., ... and 
Yamagata, K. (2008). Variants in KCNQ1 are associated with susceptibility to 
type 2 diabetes mellitus. Nature Genetics 40, 1092-1097. 
 
